

Vanadium-catalyzed selenide oxidation with *in situ* [2,3] sigmatropic rearrangement (SOS reaction): scope and asymmetric applications † ‡

T. Campbell Bourland, Rich G. Carter* and Alexandre F. T. Yokochi§

Department of Chemistry, Oregon State University, Corvallis, OR 97331, USA.

E-mail: rich.carter@oregonstate.edu; Fax: 541 737-9496; Tel: 541 737-9486

Received 19th December 2003, Accepted 20th February 2004

First published as an Advance Article on the web 31st March 2004


A vanadium-catalyzed method for the oxidation of prochiral aryl, allylic selenides with tandem [2,3] sigmatropic rearrangement has been developed. This protocol has been screened on a series of substrates to test for its generality and effectiveness. The applicability of this methodology to the synthesis of enantiomerically enriched allylic alcohols has been studied on a series of chiral oxazole-containing systems with a diastereomeric ratio (d.r.) of up to 85 : 15. The chiral transfer observed in the allyl alcohol products is the result of a net 1,9- and/or 1,10-induction. Finally, the first example of a selenium–oxygen nonbonding interaction in oxazole-containing selenide appears to have been observed *via* X-ray crystal analysis.

Introduction

Allylic alcohols are vital cogs in organic synthesis. Because of the importance of allylic alcohols as synthons, many chemists have explored a variety of pathways for the construction of this intricate subunit.¹ Chiral and achiral allylic alcohols have also been exploited to create other useful precursors including epoxides, cyclopropanes, and unsaturated diols.² In addition, allylic alcohols are present in numerous complex natural products.³

One potentially attractive method for accessing the allylic alcohol functionality is by selenide oxidation with *in situ* [2,3] sigmatropic rearrangement (SOS reaction, Scheme 1). Several laboratories have exploited this strategy and the area has been recently reviewed.⁴ A sulfur-based variant for the SOS reaction (the Mislow–Braverman–Evans rearrangement) is also well-known and has been extensively studied.^{5,6} Interestingly, the equilibrium of the sulfur-based [2,3] sigmatropic rearrangement often favors the sulfoxide, thereby requiring an *in situ* “trapping agent” such as P(OMe)₃ to force the equilibrium in the desired direction. In contrast, the selenoxide intermediate **2** undergoes rapid sigmatropic rearrangement, even at low temperatures, with the equilibrium strongly favoring the selenenates **5** and **6**. Finally, most protocols for the key selenide oxidation step rely upon stoichiometric oxidants, such as H₂O₂ and *m*-CPBA. In fact, prior to our work,⁷ no general method⁸ had been reported for a metal-catalyzed system for accomplishing this dual reaction sequence.

Several important stereochemical issues are also present in the SOS reaction. Oxidation of the prochiral allylic selenide yields a chiral selenoxide **2** which can transfer its chiral information via a [2,3] sigmatropic rearrangement to the resultant selenenates **5** and **6**. Cleavage of the Se–O bond provides the allylic alcohols **7** and **8**. Two potential pathways exist for the



Scheme 1 Selenide oxidation with *in situ* [2,3] sigmatropic rearrangement (SOS reaction).

sigmatropic rearrangement involving either an endocyclic or exocyclic transition state. Reich and co-workers calculated the *endo* pathway **3** to be approximately 2 kcal mol⁻¹ more stable than its *exo* counterpart **4**.⁹ Interestingly, Davis and co-workers studied the oxidation of prochiral selenides not capable of undergoing sigmatropic rearrangement using a chiral oxaziridine. They were able to achieve up to 97 : 3 enantiomeric ratio (e.r.) on sterically demanding aryl selenide systems. Application of their chiral oxaziridines to selenide systems capable of undergoing [2,3] sigmatropic rearrangement yielded enantiomeric excesses ranging from 40% e.e. for *E*-alkenes to 60% e.e. for *Z*-alkenes.¹⁰ These results would indicate that a considerable amount of chiral information is lost in the sigmatropic rearrangement. Despite these apparent limitations, several laboratories have been able to achieve levels of selectivity that

† A portion of this work was conducted in the Department of Chemistry and Biochemistry, University of Mississippi, Oxford, MS 38677.

‡ Electronic Supplementary Information (ESI) available: Generalized procedures and spectral data for compounds **9–14**, and X-ray crystallographic data for compounds **55** and **66**. See <http://www.rsc.org/suppdata/ob/b3/b316502g/>

§ Director of X-ray Crystallographic Facility, Department of Chemistry, Oregon State University, Corvallis, OR 97331; Alexandre.Yokochi@oregonstate.edu.

are larger than should be possible, based on the oxaziridine experiments.^{11–15} It would appear that the exact nature of the chirality transfer in the sigmatropic rearrangement continues to not be fully understood.

The potential applications of an asymmetric selenide oxidation with *in situ* [2,3] sigmatropic rearrangement (ASOS reaction) would be significant. The considerable efforts by several laboratories in this area have primarily been focused on the utilization of stoichiometric oxidants in both the SOS and the ASOS reactions.^{9–14} Due to the prevalent interest in the development of metal-catalyzed processes, our laboratory sought to explore a metal-catalyzed method for accomplishing this dual reaction sequence.


Results and discussion

Vanadium-catalyzed SOS reaction

Our preliminary investigations involved the use of a Ti(OR)₄/*t*-butyl hydroperoxide (TBHP) system, which has proven an ideal oxidation combination in numerous asymmetric transformations.¹⁶ We were disappointed to observe that both the racemic and the asymmetric variants¹⁵ of this system performed poorly in our hands with sluggish reaction rates and stoichiometric levels of the metal catalyst to proceed to completion. These results are consistent with the work done independently by the Tingoli¹⁷ and Kamigata¹⁸ laboratories using a titanium catalyst to effect selenide oxidation.

Vanadium-catalyzed oxidations¹⁹ have proven effective in the oxidation of sulfides to the corresponding sulfoxide.²⁰ Unlike titanium, these sulfide-based reactions proceed readily and usually require only a small amount of the metal catalyst. We were gratified to find that 10 mol% vanadyl acetylacetonate [VO(acac)₂], with TBHP or cumene hydroperoxide (CHP) as the co-oxidant, efficiently and rapidly induced the SOS reaction. The VO(acac)₂ was key to this tandem reaction sequence; the control experiment without VO(acac)₂ led to <5% conversion after 24 h. This catalyst system was screened on a diverse series of allylic selenides, possessing a variety of substituents on the alkene (Table 1). The selenides **9a–h** were constructed in one step from their corresponding alcohols using the commercially available *o*-NO₂C₆H₄SeCN and PBU₃ in high yield.²¹ The vanadium-catalyzed SOS reaction proved amenable to all substrates that were screened with yields ranging from 65–89%. Cleavage of the Se–O bond of the selenenate species was best accomplished using PBU₃. Traditional cleavage methods (such as pyridine/H₂O and PPh₃) proved slow and inconsistent. It is important to note, however, that Bu₃P must be added to the reaction at –10 °C. If the Se–O cleavage was performed at room temperature, a considerable amount of the 2° allylic selenide was recovered, resulting from a Mitsunobu-type S_N² inversion.

One additional area that we felt it was prudent to study was the effect of a proximal stereogenic center on the diastereomeric ratio of the resultant allylic alcohol (Scheme 2). The required



Scheme 2 Effect of proximal stereogenic centers on the vanadium-catalyzed SOS reaction.

Table 1 Selected examples of a vanadium-catalyzed SOS reaction^a

Entry	R	R'	R''	Yield ^b
a ^c	–C ₆ H ₁₃	H	H	70%
b		H	H	75%
c		H	H	84%
d ^d		H	H	66%
e		H	H	65%
f		H	CH ₃	70%
g	H	–C ₆ H ₁₃	H	89%
h ^d	H		H	86%

^a All reactions unless otherwise noted were performed at 0.3 M concentration of substrate using 1.2 eq. tributylphosphine to quench the selenenate intermediate. ^b All yields are isolated yields after chromatography over silica gel. ^c This reaction was quenched with triphenylphosphine. ^d *t*-Butyl hydroperoxide was substituted for cumene hydroperoxide to simplify purification.

chiral allylic selenides **12** and **14** were synthesized from the known Evans alkylation derivative **11**²² *via* standard methods. We were intrigued to discover that the neighboring stereogenic center had little effect on the stereochemical outcome of the SOS reaction. This result is consistent with a hypothesis that the stereochemistry of the selenoxide is the major determining factor in the configuration of the resultant allylic alcohol.¹⁰


Vanadium-catalyzed, ligand-based ASOS reaction

With the utility of the vanadium-catalyzed SOS reaction firmly established, we shifted our focus to the development of the ASOS reaction. We initially hoped to employ a chiral tri- or tetradentate Schiff base ligand system to facilitate asymmetric induction to the ultimate allylic alcohol product. Several laboratories have exploited this strategy in the asymmetric oxidation of sulfides to sulfoxides with good levels of enantioselectivity.²⁰ Based on the work by other laboratories, which showed increased levels of selectivity using the *Z*-alkene,^{10,11} the selenide **9g** was chosen as our initial substrate (Table 2). We were disappointed to observe essentially no meaningful levels of selectivity. It was thought that a more sterically demanding substituent on the alkene might help to increase the level of chiral induction from the Schiff base ligands to the selenoxide by increasing a disruptive steric interaction in the *exo* transition state of the [2,3] sigmatropic rearrangement.^{10,11,14,23} To this effect, the cyclohexyl selenide **15** was constructed *via* standard methods. This substrate proved only marginally more effective with up to 55 : 45 e.r. observed using the tetradentate ligand **17**. Ligands such as the *t*-leucinol derived ligand **20**, which provided good levels of e.r. on the sulfide to sulfoxide system, proved ineffective. It became apparent that extension of the vanadium-catalyzed methodology to a ligand-based ASOS reaction was premature.

Table 2 Selected examples of a ligand-based, vanadium-catalyzed ASOS reaction


R
 $\text{9g R} = \text{C}_6\text{H}_{15}$
 $\text{15 R} = \text{c-C}_6\text{H}_{13}$

Entry	Selenide	Ligand	e.r.
a	9g	16	<51 : 49
b	9g	17	<51 : 49
c	9g	20	<51 : 49
d	15	16	<51 : 49
e	15	17	55 : 45
f	15	18	<51 : 49
g	15	19	<51 : 49
h	15	20	53 : 47
i	15	21	<51 : 49
j	15	22	<51 : 49
k	15	23	53 : 47
l	15	24	52 : 48



Vanadium-catalyzed, oxazole-based ASOS reaction

While the promising results obtained in the catalytic, asymmetric oxidation of prochiral sulfides by other laboratories²⁰ did not correlate well with ASOS reaction using a ligand-based strategy, several other approaches have been employed for the synthesis of enantioenriched sulfoxides. Williams and co-workers published an elegant solution to the oxidation of prochiral sulfides using an oxazole-based strategy (Scheme 3).²⁴ They were able to achieve a diastereomeric ratio (d.r.) of up to 97 : 3 using a metal-catalyst [VO(acac)₂ or Ti(O*i*-Pr)₄ with the latter giving superior results]. The Williams laboratory proposed that a pre-coordinated complex between the metal and the oxazole facilitated the observed level of selectivity. This system would appear ideally suited for extension to the ASOS reaction.



Scheme 3 Williams and co-workers oxazole-based sulfide oxidation system.


Construction of the required selenide precursors was available in 3 straightforward steps (Scheme 4). The commercially available amino alcohols were condensed with 2-bromobenzoyl chloride (**31**) to give benzamides **32** and **33**. The crude benzamides were converted to the oxazole using SOCl₂. It should be noted that oxazoles **34** and **35** have been previously prepared by Zhou and Pfaltz.²⁵ Halogen-metal exchange using *t*-BuLi

Table 3 Selected examples of amino alcohol derived oxazoles in the vanadium-catalyzed ASOS reaction

$\text{38 R}_1 = \text{t-Bu, R}_2 = \text{H}$
 $\text{39 R}_1 = \text{H, R}_2 = \text{i-Pr}$
 $\text{40 R}_1 = \text{Bn, R}_2 = \text{H}$

Entry	Selenide	Oxidant	Yield	d.r. ^b
a	40 ^a	VO(acac) ₂ /TBHP	78%	55 : 45 (R)
b	39	VO(acac) ₂ /TBHP	56%	60 : 40 (S)
c	38	VO(acac) ₂ /TBHP	52%	70 : 30 (R)
d	38	<i>m</i> -CPBA	41%	52 : 48

^a Selenide **40** was prepared *via* a two step protocol starting from the commercially available amino alcohol and 2-bromobenzonitrile in the presence of zinc chloride in chlorobenzene at 140 °C followed by the standard halogen-metal exchange protocol described for selenides **38** and **39**. ^b The d.r. was determined by Mosher ester analysis using ¹H and/or ¹⁹F NMR.




Scheme 4 Synthesis of the *iso*-propyl and *tert*-butyl oxazoles. i. 2-Br-C₆H₄COCl (**31**), Et₃N, CH₂Cl₂; ii. SOCl₂, CH₂Cl₂, 50–74%; iii. *t*-BuLi, THF, –78 °C; Se powder, –78 to 0 °C then *E*-PhCH=CHCH₂Br, 61–73%.

followed by the addition of selenium powder yielded the lithiated selenolate intermediates **36** and **37**. Subsequent alkylation with cinnamyl bromide provided the required selenides **38** and **39**.

With the oxazoles **38–40** in hand, the ASOS reaction was explored under the standard VO(acac)₂ conditions (Table 3). We were pleased to find a direct correlation between the amount of steric bulk on the oxazole and the level of diastereomeric excess. In addition, these oxazole substrates **38–40** proceeded at –50 °C, unlike the *o*-NO₂ selenides **5g** and **15** in the ligand-based series which typically required temperatures of –30 °C to proceed at a reasonable rate. The (*S*)-*tert*-leucinol-based oxazole **38** gave the highest level (70 : 30 d.r.) of selectivity, which is the result of *net-1,9 asymmetric induction*. It is important to note that treatment of the *t*-butyl oxazole **38** with *m*-CPBA, the standard oxidant for most previous examples of the ASOS reaction reported in the literature,^{12–14} yielded little diastereoselectivity (52 : 48 d.r.). It was clear that the vanadium system was able to provide a *significant improvement* over previous oxidation systems. Based on these encouraging levels of

induction, the construction of more sterically demanding oxazole systems was warranted.

The corresponding camphor-based oxazoles were constructed from the known *exo* and *endo* amino alcohols **41** and **42**²⁶ (Scheme 5). Formation of the amide linkage was accomplished in an analogous fashion to the previous series. Subsequent cyclization to the required oxazole, however, required an alternative approach. Fortunately, treatment of the amides **43** and **44** with TFA in benzene at elevated temperatures cleanly provided the cyclized products **45** and **46**. Subsequent halogen-metal exchange followed by incorporation of the allylic selenides **47** and **48** proceeded in 17–27% unoptimized yield.



Scheme 5 Synthesis of the camphor-based oxazoles. i. 2-Br-C₆H₄COCl (**31**), Et₃N, CH₂Cl₂, 60%; ii. TFA, PhH, 140 °C, 50–81%; iii. *t*-BuLi, THF, –78 °C; Se powder, –78 to 0 °C then *E*-PhCH=CHCH₂Br, 17–27%.

Submission of the camphor-based selenides **47** and **48** to the standard vanadium-catalyzed ASOS reaction conditions yielded informative results (Table 4). We were surprised to discover that both the *exo* and the *endo* camphor-based oxazoles performed poorly in the vanadium-catalyzed ASOS reaction. The diastereomeric ratios for selenides **47** and **48** were significantly below the levels previously observed with the *t*-butyl oxazole **38** (70 : 30 d.r.). One possible explanation can be found in the fact that these selenides did not readily undergo oxidation at –50 °C. Only after warming the reaction an additional 10 to 15 °C was a sluggish rate observed. This apparent decrease in rate could potentially be explained by the inability of the vanadium/oxidant complex to preorganize with the oxazole prior to selenide oxidation. One option to encourage this preorganization of the vanadium/oxidant complex to the oxazole would be the incorporation of an additional Lewis base(s) on the oxazole ring system. This multidentate system should more tightly associate with the metal, thereby providing a better opportunity for transfer of the chiral information.


A serine-based oxazole would appear ideally suited to provide an additional Lewis-base for coordination (Scheme 6). The required oxazole was readily available from D- or L-serine methyl ester. The amide linkage was constructed as described previously²⁷ to provide **50**. Silylation of the free hydroxyl

Table 4 Synthesis of the camphor-based oxazoles

Entry	Selenide	Temperature	Yield	d.r.(<i>R</i> : <i>S</i>) ^a
a	47	–35 °C	50%	53 : 47
b	48	–40 °C	57%	43 : 57

^a The d.r. was determined by Mosher ester analysis using ¹H and/or ¹⁹F NMR.

function followed by reduction yielded the alcohols **51** and **52**. Oxazole formation followed by halogen-metal exchange with allylic selenide incorporation yielded the silyl protected selenides **53** and **54**. Removal of the silyl ethers was best accomplished under buffered TBAF conditions to yield the free alcohol **55**. Unbuffered TBAF conditions led to a considerable decrease in yield. The free alcohol **55** was also methylated to provide an additional selenide substrate for screening.



Scheme 6 Synthesis of the serine-based oxazoles. i. 2-Br-C₆H₄COCl (**31**), Et₃N, CH₂Cl₂, 72%; ii. TBSCl or TIPSOTf, Et₃N, DMAP, CH₂Cl₂, 70%; iii. LiAlH₄, THF, 0 °C, 62–71%; iv. TsCl, DMAP, Et₃N, CH₂Cl₂, 70–72%; v. *t*-BuLi, THF, –78 °C; Se powder, –78 to 0 °C then *E*-PhCH=CHCH₂Br, 62–71%; vi. TBAF, HOAc, THF, 76–94%; vii. MeI, NaH, THF, 82%.

The structure of selenide **55** was conclusively established by X-ray crystal analysis (Fig. 1).[¶] It is interesting to note that the oxygen, *not the nitrogen*, appears to interact with the selenium






Fig. 1 ORTEP representation of the X-ray data for the serine-derived selenide **55**.

[¶] CCDC reference numbers 228854–228855. See <http://www.rsc.org/suppdata/ob/b3/b316502g/> for crystallographic data in.cif or other electronic format.

Table 5 Synthesis of the camphor-based oxazoles

Entry	Selenide	Yield	d.r. (<i>R</i> : <i>S</i>) ^a
a	53	52%	< 45 : 55
b	55	63%	80 : 20 (<i>S</i>)
c	56	50%	< 45 : 55

^a The d.r. was determined by Mosher ester analysis using ¹H and/or ¹⁹F NMR.


Table 6 Variation of oxidant system for ASOS reaction

Entry	Oxidant system	Yield	d.r. (<i>S</i> : <i>R</i>) ^b
a ^a	Ti(Oi-Pr) ₄ (10 mol%)	47%	65 : 35
b	Ti(Oi-Pr) ₄ (100 mol%)	60%	65 : 35
c	MoO ₂ (acac) ₂ (10 mol%)	53%	62 : 38
d	Zr(acac) ₂ (10 mol%)	35%	67 : 33
e	Mn(acac) ₂ (10 mol%)	19%	67 : 34
f	<i>m</i> -CPBA (10 mol%)	63%	63 : 37
g	VO(acac)₂ (10 mol%)	63%	80 : 20

^a This reaction was performed at -50 °C to -25 °C as little to no reaction was observed at lower temperatures. ^b The d.r. was determined by Mosher ester analysis using ¹H and/or ¹⁹F NMR.

atom (2.709 Å Se–O distance). To the best of our knowledge, this compound represents the first example of a selenium–oxygen nonbonding interaction in oxazole-containing selenides.²⁸ The free hydroxyl participates in *intermolecular* hydrogen bonding with the oxazole nitrogen of another molecule, thereby blocking any nonbonding interaction between the nitrogen and selenium. Interestingly, ⁷⁷Se NMR of compounds **55** and **54** show a small difference between each other is (349.3 ppm for **55**, 354.4 ppm for **54** in CDCl₃ versus 335.8 ppm for PhSeAllyl and 387.2 ppm for **9d**) which indicates there may be a change in the nature of the interaction between the oxazole and the selenide. In comparison, ⁷⁷Se NMR chemical shifts of other oxazole-containing selenides tend to fall between 300 and 425 ppm.^{28b}

The selenides **53**, **55** and **56** were screened for utility in the vanadium-catalyzed ASOS reaction (Table 5). Silyl ether **53** provided low levels of induction, which is consistent with the TIPS ether's inability to chelate.²⁹ We were gratified to discover that the hydroxyl containing selenide **55** yielded an increase in diastereoselectivity (80 : 20 d.r.). Further support for the chelation model can be found in a reversal in the absolute configuration of the resultant alcohol **10e** versus the selenide **38**. These results support a model involving chelation of both the oxazole nitrogen and the free hydroxyl to the metal/oxidant complex, thereby situating the oxidant complex in the opposite face relative to the selenide **38**. Williams and co-workers put forth a similar model to explain their stereochemical outcome in the sulfide oxidation series (Scheme 3). It is also interesting to note that 80 : 20 d.r. is considerably higher than the level of selectivity observed by Davis and co-workers using the chiral

Table 7 Threonine-based oxazole in the ASOS reaction


Entry	Selenide	Yield	d.r. ^a
a	58	69%	58 : 42 (<i>R</i>)
b	59	74%	75 : 25 (<i>S</i>)
c	60	74%	83 : 17 (<i>S</i>)

^a The d.r. was determined by Mosher ester analysis using ¹H and/or ¹⁹F NMR.

oxaziradine oxidants on their *E*-allylic selenide (70 : 30 e.r.).¹⁰ Interestingly, submission of the methyl ether **56** to the standard vanadium-catalyzed system yielded essentially no diastereoselectivity. It would appear that the free hydroxyl function is required for selectivity.

In order to ensure that the vanadium-catalyzed system continued to be the optimum protocol for accomplishing the ASOS reaction, a series of alternative oxidant systems were screened (Table 6). As shown in Table 6, all other systems screened led to diminished levels of selectivity versus the vanadium-catalyzed protocol. It is particularly interesting to note that the titanium-based catalyst performed poorly in the ASOS reaction. The result is in stark contrast to the analogous sulfide systems by Williams in which the titanium-based system provided superior results.²⁴ In addition, *m*-CPBA, the oxidant of choice for the majority of previously reported auxiliary-based ASOS systems, yielded comparable levels of diastereoselectivity to the titanium system.

Due to the increased level of diastereoselectivity observed with the serine-based series, we sought to study the effect of an additional stereogenic center located on the hydroxyl function. Using an analogous approach as described previously, the threonine-derived oxazole was prepared (Scheme 7). Silyl deprotection of **58** using buffered TBAF conditions yielded the desired alcohol **59**. The epimeric hydroxyl function **60** was readily accessible *via* Mitsunobu inversion with *p*-NO₂ benzoic acid³⁰ followed by transesterification.




Scheme 7 Synthesis of the serine-based oxazoles. i. 2-Br-C₆H₄COCl (**31**), Et₃N, CH₂Cl₂, 58%; ii. TIPSOTf, Et₃N, CH₂Cl₂, 62%; iii. LiAlH₄, THF, 0 °C, 71%; iv. TsCl, DMAP, Et₃N, CH₂Cl₂, 63%; v. *t*-BuLi, THF, -78 °C; Se powder, -78 to 0 °C then *E*-PhCH=CHCH₂Br, 54%; vi. TBAF, HOAc, THF, 78%; vii. DEAD, *p*-NO₂-C₆H₄CO₂H, PPh₃, THF, 80%; viii. K₂CO₃, MeOH, 50%.

The threonine-based oxazoles **58–60** were screened in accord with the established vanadium-catalyzed protocol (Table 7). Once again, the silyl protected system **58** yielded low levels of diastereoselectivity. Interestingly, the free alcohol **59**, possessing the natural configurations of the amino acid, resulted in a decrease in selectivity versus the serine series. We were gratified to find, however, that the epimeric alcohol **60** lead to a further modest increase in diastereoselectivity to 83 : 17 d.r. It became apparent that the second stereogenic center, located in a *net-1,10* relationship, may be able to facilitate the transfer of additional levels of chiral information.

While the amino acid L-threonine did provide access to the oxazole possessing additional stereochemical information on the hydroxyl function, the route for the construction of the selenide oxazoles such as **59** and **60** had become lengthy. An alternate approach to the construction of oxazoles possessing this type of functionality needed to be developed in order to study the variation of the nature of the substitution on the hydroxyl function.

The previously described serine-derived alcohol **50** would appear to be the ideal starting point for a second generation synthetic strategy (Scheme 8). One important advantage to this starting point is the commercial availability of both enantiomers (D- or L- serine methyl ester) for a reasonable price. Cyclization using DAST³¹ readily provided the desired oxazole in high yield. While the reduction of the similar oxazole ester functionality has been reported in the literature,³² the resultant aldehyde is notoriously unstable. An alternative approach would involve selective monoaddition of an appropriately chosen nucleophile to the ester. While esters do not normally undergo the desired process, it was hoped that the neighboring oxazole nitrogen might help to accomplish this goal.³³ Subsequent reduction of the resultant ketone would provide access to a wide range of oxazole possessing the desired substitution pattern. We were gratified to find that addition of *i*-PrMgCl to the ester provided the desired mono addition product **62** in 74% yield. Subsequent reduction using NaBH₄ in MeOH provided both epimeric alcohols in a nearly equal (58 : 42) ratio (**63** : **64**). These alcohols were readily separable and both epimers were carried through the remaining sequence individually to provide selenides **65** and **66**. The stereochemistry of **63** and **64** was conclusively established by X-ray crystal analysis of **66**.[¶]



Scheme 8 Synthesis of the second generation serine-based oxazoles. i. DAST, CH₂Cl₂; K₂CO₃, -78 °C, 91%; ii. *i*-PrMgCl, THF, -78 °C, 74%; iii. NaBH₄, MeOH, 0 °C, 58% (**63**), 42% (**64**); iv. TBSOTf, 2,6-lutidine, CH₂Cl₂, 0 °C, 94% (from **63**), 62% (from **64**); v. *t*-BuLi, THF, -78 °C; Se powder then *E*-PhCH=CHCH₂Br, 71% (from **63**), 74% (from **64**); vi. TBAF, AcOH, CH₂Cl₂, rt, 53% (**65**), 60% (**66**).


We were gratified to discover that the added substitution on the oxazole did provide a further increase in diastereoselectivity (Table 8). The *anti*-alcohol selenide **66** yielded an 85 : 15 d.r. while the *syn*-alcohol selenide **65** provided a still significant (81 : 19 d.r.) level of chiral induction. These results are consistent with the threonine-derived series and point to the modest importance of the stereogenic center on the 2° alcohol despite its remote distance (*ten* atoms away) from the resultant allyl alcohol. Finally, we constructed the corresponding *Z*-alkene substrate **67**³⁴ and submitted the substrate to our standard reaction conditions. Interestingly, this compound provided inferior results, with only a modest 71 : 29 d.r. observed. This result differs from previous work by several laboratories in which the *Z*-alkene provided superior results.⁹⁻¹¹

Table 8 Second generation serine-based oxazoles in the ASOS reaction

Entry	Selenide	Yield	d.r. ^a
a	65	61%	81 : 19 (<i>R</i>)
b	66	71%	85 : 15 (<i>R</i>)
c	67	58%	71 : 29 (<i>S</i>)

^a The d.r. was determined by Mosher ester analysis using ¹H and/or ¹⁹F NMR.

A possible mechanistic picture is proposed in Scheme 9 to explain the observed selectivity. A bidentate complex **68/69** is formed which directs oxidation of the pro-*S* lone pair on selenium to provide the selenoxide **70/71**. Given Davies and co-workers' finding that the maximum level of induction possible with a 1,2-disubstituted *E*-alkene from a chiral selenoxide to the resultant chiral alcohol **10e** is 70 : 30 e.r. (40% chiral transfer),¹⁰ it is reasonable to assume that the vanadium/oxazole complex interacts with the intermediate selenoxide in a complementary fashion to increase the observed level of chirality transfer. The exocyclic transition states **70/71-*exo*** should be disfavored by the unfavorable interaction with the bicyclic vanadyl moiety. A similar argument could be put forth to explain why a decrease in selectivity is observed with the *Z*-cinnamyl selenide **67** (*via* **72-*endo***). It should be noted that the effect of the relative stereochemistry at C_{9,10} is complicated by the fact that *two* chirality transfer steps are occurring in the same reaction. It is possible that the alternate relative stereochemistry at these positions (*e.g.* **59** and **65**) may not work at the same synergistic level as the optimum substrates **60** and **66**. In fact, the oxidation step may proceed with greater (or reduced) levels of chirality transfer.



Scheme 9 Possible mechanistic cartoon for vanadium-catalyzed ASOS reaction. i. VO(acac)₂, TBHP, CH₂Cl₂, mol. sieves, -50 °C; PBu₃.

Conclusion

A catalytic, metal-based SOS reaction has been developed using only 10 mol% of VO(acac)₂ with either CHP or TBHP as a co-oxidant. These reactions proceed rapidly and cleanly to provide the resultant allylic alcohol in good yield. A broad spectrum of aryl, allylic selenides have been screened to demonstrate the generality of this methodology.

Considerable progress has been made toward the development of an efficient, vanadium-catalyzed ASOS reaction using a chiral oxazole-based approach. The optimum observed level of diastereomeric excess (85 : 15 d.r. for selenide **66**) is among the highest values for comparable auxiliary-based, *trans*-cinnamyl systems.¹² The chirality transfer observed in the product allyl alcohol is the result of a net 1,9- and/or 1,10-induction. A possible mechanistic cartoon is proposed to explain the observed selectivity.

It should be noted that the recovery of the chiral auxiliary from substrates such as selenide **66** should be possible. Treatment of the diselenide by-product produced in the tandem sequence with a reducing agent, such as NaBH₄, should regenerate the necessary nucleophile for alkylation with the corresponding allyl halide. While this avenue was not explored during the course of this study, other laboratories have demonstrated its feasibility.¹¹ Finally, this auxiliary-based approach should lay the foundation for the development of a ligand-based, vanadium-catalyzed ASOS reaction.

Experimental

Melting points were taken on a Mel-Temp apparatus and are uncorrected. Infrared spectra were recorded on a Perkin-Elmer paragon 500 FT-IR spectrophotometer neat unless otherwise indicated. ¹H NMR spectra were recorded on a Bruker 300 spectrometer at 300 MHz or a Bruker 500 spectrometer at 500 MHz in the indicated solvent and are reported in ppm relative to trimethylsilane and referenced internally to the residually protonated solvent. ¹³C NMR spectra were recorded on a Bruker 300 spectrometer at 75 MHz or a Bruker 500 spectrometer at 125 MHz in the solvent indicated and are reported in ppm relative to trimethylsilane and referenced internally to the residually protonated solvent. ⁷⁷Se NMR spectra were recorded on a Bruker 400 spectrometer at 76 MHz in CDCl₃ and are reported in ppm relative to dimethylselenide and referenced internally to the added dimethylselenide in the solution. Optical rotations were determined on a Rudolph Research Analytical Autopol III automatic polarimeter using a sodium lamp at 589 nm in CHCl₃.

Routine monitoring of reactions was performed using EM Science DC-Alufohlen silica gel, aluminium back TLC plates. Flash chromatography was performed with the indicated eluents on Silicycle 230–400 mesh silica gel.


Air and/or moisture sensitive reactions were performed under usual inert atmosphere conditions. Reactions requiring anhydrous conditions were performed under a blanket of argon, in glassware dried in an oven at 120 °C or by a bunsen flame, then cooled under argon. Solvents and commercial reagents were purified in accord with Perrin and Armarego³⁵ or used without further purification.

(4S)-*tert*-Butyl-2-[2-(3-phenyl-allylselanyl)-phenyl]-4,5-dihydro-oxazole (**38**)

To a stirred solution of oxazole **34** (122 mg, 0.43 mmol) in THF (6.5 mL) at –78 °C was added *t*-BuLi (0.4 mL, 0.65 mmol, 1.7 M in pentane) dropwise over 20 min resulting in an orange color. After 1 h, Se powder (34.2 mg 0.43 mmol) was added in 1 portion under an inverse argon funnel and warmed to 0 °C. After 1 h or until the slurry was homogeneous, cinnamyl bromide (85 mg, 53 μL, 0.43 mmol) was added. After an additional 1 h, the reaction was quenched with sat. aq. NH₄Cl (5 mL) and

the product was extracted with Et₂O (3 × 50 mL). The dried (MgSO₄) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel eluting with 2–20% EtOAc/hexane. The final product was recrystallized in hexane to yield **38** (105 mg, 61%) as a white solid: mp 138–141 °C; [α]_D²³ –77.9 (*c* 1.00, CHCl₃); IR (neat) 2959, 1644, 1353, 957 cm^{–1}; ¹H NMR (300 MHz, CDCl₃) δ 7.82 (d, *J* = 7.7 Hz, 1H), 7.48 (d, *J* = 8.0 Hz, 1H), 7.17–7.37 (m, 7H), 6.83 (d, *J* = 15.7 Hz, 1H), 6.42 (dt, *J* = 7.4, 15.7 Hz, 1H), 4.28–4.34 (m, 1H), 4.14–4.23 (m, 2H), 3.71 (d, *J* = 7.2 Hz, 2H), 0.99 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 162.7, 137.2, 136.8, 133.1, 130.9, 130.3, 128.7, 128.1, 127.6, 126.7, 126.5, 125.5, 124.7, 76.8, 68.4, 34.2, 28.8, 26.2; HRMS (FAB+) calcd. for C₂₂H₂₆NO⁸⁰Se (M + H⁺) 400.1180. Found 400.1172.

(4R)-Isopropyl-2-[2-(3-phenyl-allylselanyl)-phenyl]-4,5-dihydro-oxazole (**39**)



To a stirred solution of *t*-BuLi (4.12 mL, 7.0 mmol, 1.7 M in pentane) in THF (21 mL) at –78 °C was added the bromide **35** (0.94 g, 3.50 mmol) in THF (11 mL) dropwise *via* syringe pump over 30 min resulting in an orange solution. The benzamide conical vial was further rinsed with an additional amount of THF (2 mL). After 1 h, Se powder (290 mg, 3.7 mmol) was added under an inverse argon funnel and the reaction was then warmed to 0 °C. After 1 h or until the solution was homogeneous, cinnamyl bromide (723 mg, 0.53 mL, 3.70 mmol) was added. After 1 h, the reaction was quenched with sat. aq. NH₄Cl (5 mL) and extracted with Et₂O (3 × 75 mL). The dried (MgSO₄) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 2–20% EtOAc/hexane. The final product was recrystallized in hexane to give **39** (981 mg, 73%) as a white solid: mp 122–125 °C; [α]_D²³ +67.6 (*c* 1.00, CHCl₃); IR (neat) 2955, 1645, 1363, 1251 cm^{–1}; ¹H NMR (300 MHz, CDCl₃) δ 7.82 (dd, *J* = 1.6, 7.8 Hz, 1H), 7.48 (d, *J* = 8.1 Hz, 1H), 7.18–7.37 (m, 7H), 6.61 (d, *J* = 15.7 Hz, 1H), 6.40 (dt, *J* = 7.4, 15.7 Hz, 1H), 4.39 (dd, *J* = 7.8, 8.9 Hz, 1H), 4.20 (dd, *J* = 7.8, 14.7 Hz, 1H), 4.10 (dd, *J* = 7.6, 15.3 Hz, 1H), 3.71 (d, *J* = 7.5 Hz, 2H), 1.80–1.84 (m, 1H), 1.08 (d, *J* = 6.7 Hz, 3H), 0.97 (d, *J* = 6.7 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 161.4, 137.1, 136.5, 133.1, 130.9, 130.2, 128.7, 128.1, 127.6, 126.4, 125.4, 124.7, 77.2, 73.6, 70.2, 33.4, 28.8, 19.3, 18.8; HRMS (FAB+) calcd. for C₂₁H₂₄NO⁸⁰Se (M + H⁺) 386.1023. Found 386.1024.

(4S)-Benzyl-2-[2-(3-phenyl-allylselanyl)-phenyl]-4,5-dihydro-oxazole (**40**)

To a stirred solution of *t*-BuLi (1.18 mL, 2.00 mmol, 1.7 M in pentane) in THF (6 mL) at –78 °C was added a solution of the known oxazole **34a**²⁵ (311 mg, 1.00 mmol) in THF (3 mL), dropwise *via* syringe pump over 20 min resulting in an orange solution. After 1 h, Se powder (79 mg, 1.00 mmol) was added under an inverse argon funnel and the reaction was warmed to 0 °C. After 1 h or until the mixture was homogeneous, cinnamyl bromide (196.7 mg, 0.15 mL, 1 mmol) was added. After an additional 1 h, the reaction was quenched with sat. aq. NH₄Cl (10 mL) and extracted with Et₂O (3 × 75 mL). The dried (MgSO₄) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 2–20% EtOAc/hexane to yield **40** (46.3 mg, 10%) as a pale yellow oil: IR (neat) 2959, 1643; 1589 cm^{–1}; ¹H NMR (CDCl₃, 300 MHz) δ 7.80 (d, *J* = 7.8 Hz, 1H), 7.48 (d, *J* = 7.9 Hz, 1H), 7.18–7.37 (m, 12H), 6.62 (d, *J* = 15.6 Hz, 1H), 6.42 (dt, *J* = 7.4,

15.2 Hz, 1H), 4.68 (m, 1H), 4.31 (dd, $J = 8.7, 8.7$ Hz, 1H), 4.08–4.15 (m, 1H), 3.73 (d, $J = 7.3$ Hz, 2H), 3.29 (dd, $J = 5.4, 13.7$ Hz, 1H), 2.78 (dd, $J = 8.6, 13.6$ Hz, 1H).

2-Bromo-*N*-{(3*R*)-hydroxy-4*R*,7,7-trimethyl-bicyclo[2.2.1]hept-(2*S*)-yl}-benzamide (43)

To a stirred solution of amino alcohol **41**²⁶ (808.0 mg, 4.78 mmol) in CH₂Cl₂ (9 mL) at 0 °C were sequentially added DMAP (146.0 mg, 1.20 mmol) and Et₃N (627.1 mg, 0.86 mL). After 10 min, a solution of 2-bromobenzoyl chloride **31** (1.05 g, 0.63 mL, 4.00 mmol) in CH₂Cl₂ (4.8 mL) was added dropwise *via* syringe pump over 20 min. After an additional 30 min, the reaction was warmed to rt. After 2 h, the reaction was quenched with sat. aq. NH₄Cl (25 mL) and extracted with Et₂O (3 × 75 mL). The organic layer was sequentially washed with aq. HCl (5%, 50 mL) and sat. aq. NaHCO₃ (100 mL). The dried (MgSO₄) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 2–40% EtOAc/hexane to give **43** (842 mg, 60%) as a light pink solid: mp 169–170 °C; [α]_D²³ –3.1 (*c* 0.72, CHCl₃); IR (neat) 3381; 1651, 1506 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.58 (d, $J = 7.9$ Hz, 1H), 7.52 (dd, $J = 1.5, 7.7$ Hz, 1H), 7.23–7.37 (m, 2H), 6.67 (br s, 1H), 4.00 (dd, $J = 6.8, 13.4$ Hz, 1H), 3.91 (dd, $J = 7.6, 4.14$ Hz, 1H), 2.17 (br s, 1H), 1.99 (d, $J = 4.4$ Hz, 1H), 1.27–1.57 (m, 4H), 1.23 (s, 3H), 1.21 (s, 3H), 1.15 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 167.7, 138.3, 133.6, 131.3, 129.6, 127.6, 119.6, 80.1, 58.6, 50.4, 49.4, 47.1, 33.4, 26.4, 21.7, 21.4, 11.5; HRMS (FAB+) calcd. for C₁₇H₂₃NO₂⁷⁹Br (M + H⁺) 352.0912. Found 352.0922.

4-(2-Bromo-phenyl)-1,10,10-trimethyl-(3*R*)-oxa-(5*S*)-azatricyclo[5.2.1.0]dec-4-ene (45)

To a stirred solution of alcohol **43** (137.9 mg, 0.393 mmol) in benzene (1.1 mL) was added TFA (9.1 mg, 6.0 μ L, 0.08 mmol) and powdered 4 Å mol. sieves (50 mg). After 10 min, the reaction was heated to 140 °C in a sealed tube. After 8 h, the reaction was cooled to rt and quenched with sat. aq. NaHCO₃ (10 mL) and extracted with Et₂O (3 × 50 mL). The dried (MgSO₄) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 2–25% EtOAc/hexane to give **45** (65 mg, 50%) as a white solid: mp 142 °C; [α]_D²³ +10.9 (*c* 1.3, CHCl₃); IR (neat) 2950; 1651, 1506 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.58–7.80 (m, 2H), 7.26–7.38 (m, 2H), 4.43 (d, $J = 8.6$ Hz, 1H), 4.24 (d, $J = 8.6$ Hz, 1H), 2.20 (d, $J = 4.5$ Hz, 1H), 1.65–1.85 (m, 1H), 1.45–1.60 (m, 1H), 0.95–1.10 (m, 2H), 1.07 (s, 3H), 1.01 (s, 3H), 0.87 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 164.1, 134.4, 131.7, 131.5, 129.9, 127.2, 122.0, 91.7, 77.0, 49.0, 48.9, 47.3, 32.3, 26.2, 23.6, 19.0, 11.6; HRMS (FAB+) calcd. for C₁₇H₂₁NO⁷⁹Br (M + H⁺) 334.0807. Found 334.0813.

1,10,10-Trimethyl-4-[2-(3-phenyl-allyl)selanyl]-phenyl)-(3*S*)-oxa-(5*R*)-azatricyclo[5.2.1.0]dec-4-ene (47)

To a stirred solution of *t*-BuLi (1.18 mL, 2.00 mmol, 1.7 M in pentane) in THF (6.3 mL) at –78 °C was added a solution of benzamide **45** (328 mg, 0.99 mmol) in THF (3 mL) dropwise *via* syringe pump over 10 min. The benzamide conical vial was further rinsed with an additional amount of THF (1.5 mL). After 1 h, Se powder (79 mg, 1.00 mmol) was added under an inverse argon funnel and the reaction was warmed to 0 °C. After 1 h or until the solution was homogeneous, cinnamyl bromide (200 mg, 0.15 mL, 1.00 mmol) was added to the reaction. After 1 h, the reaction was quenched with sat. aq. NH₄Cl (15 mL) and extracted with Et₂O (3 × 75 mL). The dried (MgSO₄) organic layer was concentrated *in vacuo* and purified by chromatography on silica gel, eluting with 2–20% EtOAc/hexane. The final product was recrystallized in hexane to give **47** (122 mg, 27%) as a pale yellow solid: mp 155–160 °C; [α]_D²³

+5.9 (*c* 2.76, CHCl₃); IR (neat) 2955, 1641 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.82 (dd, $J = 1.1, 7.7$ Hz, 1H), 7.45 (d, $J = 8.0$ Hz, 1H), 7.17–7.36 (m, 7H), 6.61 (d, $J = 15.7$ Hz, 1H), 6.41 (dt, $J = 7.5, 15.7$ Hz, 1H), 4.37 (d, $J = 8.4$ Hz, 1H), 4.31 (d, $J = 8.4$ Hz, 1H), 3.71 (d, $J = 7.4$ Hz, 2H), 2.20 (d, $J = 4.5$ Hz, 1H), 1.70–1.90 (m, 1H), 1.50–1.65 (m, 1H), 0.95–1.10 (m, 2H), 1.11 (s, 3H), 1.09 (s, 3H), 0.89 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 164.6, 137.1, 136.6, 133.2, 131.0, 130.5, 128.7, 128.0, 127.6, 127.0, 126.4, 125.1, 124.7, 91.0, 77.0, 49.2, 48.8, 47.2, 32.3, 28.7, 26.2, 23.7, 18.9, 11.7; HRMS (FAB+) calcd. for C₂₆H₃₀NO⁸⁰Se (M + H⁺) 452.1493. Found 452.1486.

2-Bromo-*N*-[(3*S*)-hydroxy-4,7,7-trimethyl-bicyclo[2.2.1]hept-(2*R*)-yl]-benzamide (44)

To a stirred solution the amino alcohol **42**²⁶ (890.1 mg, 5.23 mmol) in CH₂Cl₂ (10 mL) at 0 °C was added Et₃N (700 mg, 0.951 mL, 6.85 mmol) and DMAP (160 mg, 1.30 mmol). After 10 min, a solution of 2-bromobenzoyl chloride **31** (1.25 g, 0.69 mL, 5.30 mmol) in CH₂Cl₂ (5 mL) was added dropwise *via* syringe pump over a period of 20 min and warmed to rt. After 2 h, the reaction was quenched with sat. aq. NH₄Cl (10 mL) and extracted with Et₂O (3 × 75 mL). The organic layer was sequentially washed with aq. HCl (50 mL, 5%) and sat. aq. NaHCO₃ (100 mL). The dried (MgSO₄) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 3–40% EtOAc/hexane to give **44** (1.53 g, 81%) as a white solid: mp 92–95 °C; [α]_D²³ –10.4 (*c* 1.29, CHCl₃); IR (neat) 3381; 1651, 1506 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.23–7.59 (m, 4H), 6.79 (br s, 1H), 4.00 (dd, $J = 6.8, 13.4$ Hz, 1H), 3.91 (dd, $J = 4.14, 7.6$ Hz, 1H), 2.17 (br s, 1H), 1.27–1.57 (m, 5H), 1.23 (s, 3H), 1.21 (s, 3H), 1.15 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 167.7, 143.0, 133.6, 131.3, 129.6, 127.6, 119.6, 80.1, 58.6, 50.4, 49.4, 47.1, 33.4, 26.4, 21.7, 21.4, 11.5; HRMS (FAB+) calcd. for C₁₇H₂₃NO₂⁷⁹Br (M + H⁺) 352.0912. Found 352.0911.

4-(2-Bromo-phenyl)-1,10,10-trimethyl-(3*S*)-oxa-(5*R*)-azatricyclo[5.2.1.0]dec-4-ene (46)

To a stirred solution of alcohol **44** (1.50 g, 4.32 mmol) in benzene (12 mL) at rt was added TFA (90 mg, 66 μ L, 0.85 mmol) and powdered 4 Å mol. sieves (200 mg). After 10 min, the reaction was heated to 140 °C in a sealed tube. After 24 h, the reaction was cooled to rt and quenched with sat. aq. NaHCO₃ (40 mL) and extracted with Et₂O (3 × 100 mL). The dried (MgSO₄) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 2–25% EtOAc/hexane to give **46** (587 mg, 41%) as a white solid: mp 110 °C; [α]_D²³ –6.9 (*c* 0.85, CHCl₃); IR (neat) 2950; 1651, 1506 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.79 (dd, $J = 1.2, 7.7$ Hz, 1H), 7.66 (dd, $J = 1.2, 7.9$ Hz, 1H), 7.26–7.38 (m, 2H), 4.77 (dd, $J = 4.8, 9.8$ Hz, 1H), 4.68 (dd, $J = 1.5, 9.9$ Hz, 1H), 2.19 (t, $J = 4.2$ Hz, 1H), 1.51–1.69 (m, 2H), 1.25–1.29 (m, 2H), 1.00 (s, 3H), 0.99 (s, 3H), 0.98 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 163.0, 134.2, 131.7, 131.6, 130.3, 127.2, 121.9, 89.4, 72.3, 49.7, 49.5, 49.4, 27.4, 20.9, 20.0, 18.6, 15.2; HRMS (FAB+) calcd. for C₁₇H₂₁NO⁷⁹Br (M + H⁺) 334.0807. Found 334.0818.

1,10,10-Trimethyl-4-[2-(3-phenyl-allyl)selanyl]-phenyl)-(3*S*)-oxa-(5*R*)-azatricyclo[5.2.1.0]dec-4-ene (48)


To a stirred solution of *t*-BuLi (3.33 mL, 5.64 mmol, 1.7 M in pentane) in THF (18 mL) at –78 °C, was added a solution of benzamide **46** (938 mg, 2.82 mmol) in THF (8.5 mL) dropwise over 20 min resulting in an orange solution. The benzamide conical vial was further rinsed with an additional amount of THF (2 mL). After 1 h, Se powder (223 mg, 2.82 mmol) was added under an inverse argon funnel and the reaction was then warmed to 0 °C. After 1 h or until the solution was homo-

geneous, cinnamyl bromide (800 mg, 0.43 mL, 2.9 mmol) was added. After 1 h, the reaction was quenched with sat. aq. NH_4Cl (20 mL) and extracted with Et_2O (3×75 mL). The dried (MgSO_4) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 2–20% EtOAc /hexane. The final product was recrystallized in hexane to give **48** (215 mg, 17%) as a white solid: mp 154–155 °C; $[\alpha]_{\text{D}}^{23} -12.4$ (*c* 1.19, CHCl_3); IR (neat) 2949, 1635 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.92 (dd, $J = 1.4, 7.7$ Hz, 1H), 7.47 (d, $J = 7.7$ Hz, 1H), 7.20–7.38 (m, 7H), 6.61 (d, $J = 15.7$ Hz, 1H), 6.41 (dt, $J = 7.5, 15.2$ Hz, 1H), 4.81 (dd, $J = 4.7, 9.7$ Hz, 1H), 4.64 (dd, $J = 1.6, 9.8$ Hz, 1H), 3.71 (d, $J = 7.4$ Hz, 2H), 2.19 (t, $J = 4.3$ Hz, 1H), 1.40–1.60 (m, 3H), 1.10–1.35 (m, 1H), 1.00 (s, 6H), 0.96 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 163.2, 137.1, 136.5, 133.2, 130.9, 130.4, 128.7, 128.1, 127.6, 127.2, 126.4, 125.2, 124.7, 88.5, 72.4, 49.7, 49.5, 49.3, 28.8, 27.3, 21.0, 20.1, 18.6, 15.2; HRMS (FAB+) calcd. for $\text{C}_{26}\text{H}_{30}\text{NO}^{80}\text{Se}$ ($\text{M} + \text{H}^+$) 452.1493. Found 452.1492.

(2S)-(2-Bromo-benzoylamino)-3-hydroxy-propionic acid methyl ester (**50**)

To a stirred solution of L-serine methyl ester hydrochloride (**49**) (2.11 g, 13.56 mmol) in CH_2Cl_2 (26 mL) at 0 °C, was added Et_3N (3.2 g, 4.34 mL, 31.2 mmol) and DMAP (0.331 g, 2.71 mmol). After 10 min, a solution of 2-bromobenzoyl chloride (**31**) (3.30 g, 1.85 mL, 14.9 mmol) in CH_2Cl_2 (15 mL) was added dropwise to the amino alcohol solution *via* syringe pump over a period of 20 min. Next, the solution was warmed to rt. After 2 h, the reaction mixture was quenched with sat. aq. NH_4Cl (50 mL) and extracted with Et_2O (3×75 mL). The organic layer was sequentially washed with aq. HCl (50 mL, 5%) and sat. aq. NaHCO_3 (100 mL). The dried (MgSO_4) organic layer was concentrated *in vacuo* and purified by chromatography on silica gel, eluting with 2–100% EtOAc /hexane to give **50** (2.94 g, 72%) as a clear oil: $[\alpha]_{\text{D}}^{23} +21.2$ (*c* 2.67, CHCl_3); IR (neat) 3335, 1734, 1652 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.54–7.61 (m, 2H), 7.25–7.38 (m, 2H), 7.00 (d, $J = 6.8$ Hz, 1H), 4.80–4.90 (m, 1H), 4.06–4.14 (m, 2H), 3.83 (s, 3H), 1.24 (t, $J = 7.0$ Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 170.7, 168.3, 137.0, 133.4, 131.6, 129.4, 127.5, 119.5, 62.4, 55.2, 52.7.

(2S)-(2-Bromo-benzoylamino)-3-triisopropylsilyloxy-propionic acid methyl ester (**73**)




To a stirred solution of amino alcohol methyl ester **50** (2.68 g, 8.90 mmol) in CH_2Cl_2 (25 mL) at 0 °C, was added Et_3N (2.07 g, 2.85 mL, 20.5 mmol). After 10 min, TIPSOTf (3.25 g, 2.9 mL, 10.6 mmol) was added. After 2 h, the reaction was quenched with sat. aq. NH_4Cl (50 mL) and extracted with Et_2O (3×100 mL). The dried (MgSO_4) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 2–20% EtOAc /hexane to give **73** (3.11 g, 70%) as a yellow oil: $[\alpha]_{\text{D}}^{23} +50.8$ (*c* 0.86, CHCl_3); IR (neat) 2942, 1748, 1652 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.58–7.63 (m, 2H), 7.21–7.34 (m, 2H), 6.97 (d, $J = 8.0$ Hz, 1H), 4.91 (dt, $J = 2.8, 8.1$ Hz, 1H), 4.28 (dd, $J = 2.5, 9.9$ Hz, 1H), 4.12 (dd, $J = 2.9, 9.8$ Hz, 1H), 3.79 (s, 3H), 1.00–1.10 (m, 21H); ^{13}C NMR (75 MHz, CDCl_3) δ 170.7, 167.2, 137.2, 133.7, 131.7, 129.9, 127.7, 119.6, 64.1, 55.1, 52.6, 18.0, 12.0; HRMS (FAB+) calcd. for $\text{C}_{20}\text{H}_{32}\text{Si}^{79}\text{BrNO}_4$ ($\text{M} + \text{H}^+$) 458.1362. Found 458.1370.

2-Bromo-N-[(2R)-hydroxy-1-(triisopropyl-silyloxy)methyl]-ethyl-benzamide (**51**)

To a stirred solution of LiAlH_4 (3.5 mL, 3.5 mmol, 1 M in Et_2O) in THF (26 mL) at 0 °C was added a solution of benzamide **73** (1.50 g, 3.19 mmol) in THF (17.4 mL) dropwise *via* syringe pump over 30 min. The benzamide flask was rinsed with an additional amount of THF (2 mL). After 2 h, the reaction was quenched with a 1 : 1 mixture of $\text{EtOAc}/\text{H}_2\text{O}$ (20 mL) and extracted with EtOAc (3×75 mL). The dried (MgSO_4) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 2–50% EtOAc /hexane to give **51** (1.01 g, 71%) as a light pink oil: $[\alpha]_{\text{D}}^{23} +10.0$ (*c* 4.48, CHCl_3); IR (neat) 3419, 2942, 2865, 1651, 1635, 1539 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.55–7.61 (m, 2H), 7.26–7.39 (m, 2H), 6.78 (d, $J = 7.3$ Hz, 1H), 4.15–4.30 (m, 1H), 4.00 (d, $J = 3.6$ Hz, 2H), 3.98–4.00 (m, 1H), 3.84–3.90 (m, 1H), 2.9 (br s, 1H), 1.00–1.10 (m, 21H); ^{13}C NMR (75 MHz, CDCl_3) δ 167.9, 137.6, 133.6, 131.5, 129.8, 127.7, 119.4, 64.5, 63.9, 52.6, 18.1, 11.9; HRMS (FAB+) calcd. for $\text{C}_{19}\text{H}_{32}^{79}\text{BrNO}_3\text{Si}$ ($\text{M} + \text{H}^+$) 430.1413. Found 430.1421.

(2S)-(2-Bromo-benzoylamino)-3-(tert-butyl-dimethyl-silyloxy)-propionic acid methyl ester (**74**)




To a stirred solution of amino alcohol methyl ester **50** (1.60 g, 5.32 mmol) in CH_2Cl_2 (11 mL) at 0 °C was added Et_3N (1.13 g, 1.55 mL, 20.5 mmol) and DMAP (0.129 g, 1.06 mmol). After 10 min, TBSCl (1.20 g, 8.02 mmol) was added and warmed to rt. After 2 h, the reaction was quenched with sat. aq. NH_4Cl (50 mL) and extracted with Et_2O (3×100 mL). The dried (MgSO_4) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 1–20% EtOAc /hexane to give **74** (1.55 g, 70%) as a yellow oil: $[\alpha]_{\text{D}}^{23} +26.3$ (*c* 0.50, CHCl_3); IR (neat) 2360, 1748, 1652, 1506 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.58–7.63 (m, 2H), 7.21–7.34 (m, 2H), 6.97 (d, $J = 7.8$ Hz, 1H), 4.91 (dt, $J = 2.8, 8.1$ Hz, 1H), 4.18 (dd, $J = 2.8, 10.2$ Hz, 1H), 4.00 (dd, $J = 2.7, 10.3$ Hz, 1H), 3.79 (s, 3H), 0.87 (s, 9H), 0.04 (s, 6H); ^{13}C NMR (75 MHz, CDCl_3) δ 170.7, 167.2, 137.2, 133.7, 131.7, 130.0, 127.7, 119.6, 63.6, 55.0, 52.6, 25.8, 18.3, -5.2, -5.4; HRMS (FAB+) calcd. for $\text{C}_{17}\text{H}_{26}\text{BrSiNO}_4$ ($\text{M} + \text{H}^+$) 416.0893. Found 416.0903.

2-Bromo-N-[1-(tert-butyl-dimethyl-silyloxy)methyl]-2(R)-hydroxy-ethyl-benzamide (**52**)

To a stirred solution of LiAlH_4 (19.8 mL, 19.8 mmol, 1 M in Et_2O) in THF (150 mL) at 0 °C was added a solution of benzamide **74** (7.45 g, 18.04 mmol) in THF (100 mL) dropwise *via* syringe pump over 30 min. The benzamide flask was rinsed with an additional amount of THF (5 mL). After 2 h, the reaction was quenched with a 1 : 1 mixture of $\text{EtOAc}/\text{H}_2\text{O}$ (100 mL) and extracted with EtOAc (3×75 mL). The dried (MgSO_4) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 2–80% EtOAc /hexane to give **52** (4.62 g, 62%) as a pink oil: $[\alpha]_{\text{D}}^{23} +15.7$ (*c* 0.50, CHCl_3); IR (neat) 3419, 2953, 1652, 1635, 1540 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.55–7.61 (m, 2H), 7.26–7.39 (m, 2H), 6.78 (br d, $J = 7.3$ Hz, 1H), 4.15–4.25 (m, 1H), 3.90–4.00 (m, 1H), 3.95 (d, $J = 6.6$ Hz, 2H), 3.80–3.90 (m, 1H), 2.85–2.95 (m, 1H), 0.89 (s, 9H), 0.10 (s, 3H), 0.08 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 167.9, 137.6, 133.6, 131.6, 129.9, 127.7, 119.4, 64.1, 63.9, 52.4, 26.0, 18.3, -5.2, -5.3.

2-(2-Bromo-phenyl)-(4R)-(triisopropyl-silanyloxymethyl)-4,5-dihydro-oxazole (75)




To a stirred solution of benzamide **51** (1.29 g, 3.01 mmol) in CH_2Cl_2 (10.3 mL) at 0°C , was sequentially added DMAP (74 mg, 0.6 mmol) and Et_3N (0.46 g, 0.63 mL, 4.58 mmol). After 10 min, TsCl (68 mg, 3.6 mmol) was added and the reaction was warmed to rt. After 12 h, the reaction was quenched with sat. aq. NH_4Cl (50 mL) and extracted with Et_2O (3×75 mL). The dried (MgSO_4) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 2–20% EtOAc /hexane to give **75** (997 mg, 70%) as a light pink oil: $[\alpha]_{\text{D}}^{23} -26.5$ (c 1.87, CHCl_3); IR (neat) 2941, 1648, 1465 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.70 (dd, $J = 1.9, 7.6$ Hz, 1H), 7.65 (dd, $J = 1.5, 7.5$ Hz, 1H), 7.25–7.36 (m, 2H), 4.45–4.55 (m, 3H), 4.00–4.10 (m, 1H), 3.75–3.85 (m, 1H), 1.00–1.10 (m, 21H); ^{13}C NMR (75 MHz, CDCl_3) δ 164.4, 134.0, 131.7, 131.5, 130.1, 127.2, 121.9, 70.7, 68.8, 65.3, 18.1, 12.1; HRMS (FAB+) calcd. for $\text{C}_{19}\text{H}_{31}\text{NO}_2^{79}\text{BrSi}$ ($\text{M} + \text{H}^+$) 412.1307. Found 412.1314.

2-[2-(3-Phenyl-allylselanyl)-phenyl]-(4R)-(triisopropyl-silanyloxymethyl)-4,5-dihydro-oxazole (53)

To a stirred solution of *t*-BuLi (1.23 mL, 2.10 mmol, 1.7 M in pentane) in THF (6.6 mL) at -78°C , was added a solution of benzamide **75** (342 mg, 0.84 mmol) in THF (2.7 mL) dropwise *via* syringe pump over 20 min. The benzamide conical vial was further rinsed with an additional amount of THF (0.5 mL). After 1 h, Se powder (66 mg, 0.84 mmol) was added under an inverse argon funnel and the reaction was warmed to 0°C . After 1 h or until the solution was homogeneous, cinnamyl bromide (197 mg, 0.26 mL, 1.0 mmol) was added. After 1 h, the reaction was quenched with sat. aq. NH_4Cl (20 mL) and extracted with Et_2O (3×50 mL). The dried (MgSO_4) organic layer was concentrated *in vacuo* and purified by chromatography on silica gel, eluting with 2–20% EtOAc /hexane. The final product was recrystallized in hexane to give **53** (266 mg, 62%) as a white solid: mp 73°C ; $[\alpha]_{\text{D}}^{23} -4.2$ (c 3.41, CHCl_3); IR (neat) 2941, 1644, 1469 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.85 (d, $J = 7.6$ Hz, 1H), 7.46 (d, $J = 8.0$ Hz, 1H), 7.18–7.37 (m, 7H), 6.63 (d, $J = 15.7$ Hz, 1H), 6.42 (dt, $J = 7.3, 15.3$ Hz, 1H), 4.50–4.55 (m, 1H), 4.41–4.44 (m, 2H), 4.07 (dd, $J = 3.9, 9.7$ Hz, 1H), 3.65–3.75 (m, 3H), 1.00–1.10 (m, 21H); ^{13}C NMR (75 MHz, CDCl_3) δ 164.3, 137.0, 136.3, 133.2, 131.0, 130.4, 128.7, 128.3, 127.6, 127.0, 126.4, 125.1, 124.8, 70.3, 69.1, 65.8, 28.8, 18.1, 12.1; HRMS (FAB+) calcd. for $\text{C}_{28}\text{H}_{30}\text{NO}_2^{80}\text{SeSi}$ ($\text{M} + \text{H}^+$) 530.1994. Found 530.1986.

2-(2-Bromo-phenyl)-(4R)-(tert-butyl-dimethyl-silanyloxymethyl)-4,5-dihydro-oxazole (76)



To a stirred solution of benzamide **52** (4.49 g, 11.6 mmol) in CH_2Cl_2 (22 mL) at 0°C , was added DMAP (283 mg, 2.3 mmol) and Et_3N (2.47 g, 3.4 mL, 24.4 mmol). After 10 min, TsCl (2.41 g, 12.8 mmol) was added and the reaction was warmed to rt. After 12 h, the reaction was quenched with aqueous NH_4Cl (50 mL) and extracted with Et_2O (3×75 mL). The dried (MgSO_4) organic layer was concentrated *in vacuo* and purified by chromatography on silica gel, eluting with 2–20% EtOAc /hexane to give **76** (3.42 g, 72%) as a light pink oil: $[\alpha]_{\text{D}}^{23} -27.7$

(c 1.00, CHCl_3); IR (neat) 2929, 1652 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.70 (dd, $J = 1.9, 7.6$ Hz, 1H), 7.65 (dd, $J = 1.5, 7.5$ Hz, 1H), 7.26–7.33 (m, 2H), 4.40–4.50 (m, 3H), 3.90 (dd, $J = 3.4, 9.8$ Hz, 1H), 3.70 (dt, $J = 3.1, 5.9$ Hz, 1H), 0.89 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 164.4, 134.0, 131.8, 131.5, 130.0, 127.2, 121.9, 70.5, 68.7, 64.9, 26.0, 18.4, $-5.0, -5.1$; HRMS (FAB+) calcd. for $\text{C}_{16}\text{H}_{25}\text{NO}_2^{79}\text{BrSi}$ ($\text{M} + \text{H}^+$) 370.0838. Found 370.0842.

(4R)-(tert-Butyl-dimethyl-silanyloxymethyl)-2-[2-(3-phenyl-allylselanyl)-phenyl]-4,5-dihydro-oxazole (54)

To a stirred solution of oxazole **76** (1.08 g, 2.93 mmol) in THF (27 mL) at -78°C , was added *t*-BuLi (3.45 mL, 5.86 mmol, 1.7 M in pentane) dropwise *via* syringe pump over 20 min. After 1 h, Se powder (234 mg, 2.92 mmol) was added under an inverted argon funnel and the reaction was warmed to 0°C . After 1 h or until the solution was homogeneous, cinnamyl bromide (583 mg, 0.44 mL, 2.96 mmol) was added. After 1 h, the reaction was quenched with sat. aq. NH_4Cl (50 mL) and extracted with Et_2O (3×50 mL). The dried (MgSO_4) organic layer was concentrated *in vacuo* and purified by chromatography on silica gel, eluting with 0–10% Et_2O /hexane to give **54** (1.01 g, 71%) as a white solid: mp $104\text{--}106^\circ\text{C}$; $[\alpha]_{\text{D}}^{23} -10.2$ (c 1.20, CHCl_3); IR (neat) 2926, 1639, 1469 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.84 (dd, $J = 1.6, 7.8$ Hz, 1H), 7.46 (d, $J = 7.8$ Hz, 1H), 7.18–7.37 (m, 7H), 6.63 (d, $J = 15.7$ Hz, 1H), 6.42 (dt, $J = 7.6, 15.2$ Hz, 1H), 4.46–4.53 (m, 1H), 4.40–4.42 (m, 2H), 3.96 (dd, $J = 4.0, 10.0$ Hz, 1H), 3.73 (d, $J = 7.4$ Hz, 2H), 3.61 (dd, $J = 7.2, 9.8$ Hz, 1H), 0.86 (s, 9H), 0.06 (s, 3H), 0.04 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 164.3, 137.0, 136.2, 133.2, 131.0, 130.4, 128.7, 128.3, 127.6, 126.9, 126.4, 125.1, 124.8, 70.1, 68.9, 65.3, 28.8, 26.0, 18.0, -5.0 ; ^{77}Se NMR (CDCl_3) 354.4; HRMS (FAB+) calcd. for $\text{C}_{25}\text{H}_{34}\text{NO}_2^{80}\text{SeSi}$ ($\text{M} + \text{H}^+$) 488.1524. Found 488.1526.

{2-[2-(3-Phenyl-allylselanyl)-phenyl]-4,5-dihydro-oxazol-(4S)-yl}-methanol (55)

To a stirred solution of selenide **53** (97 mg, 0.18 mmol) in THF (1.8 mL) at rt were sequentially added acetic acid (33 mg, 32 μL , 0.55 mmol) and TBAF (0.74 mL, 0.74 mmol, 1 M in THF). After 1 h, the reaction was quenched with sat. aq. NH_4Cl (10 mL) and extracted with EtOAc (3×25 mL). The dried (MgSO_4) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 2–60% EtOAc /hexane to give **53** (52 mg, 76%) as a white solid; mp $113\text{--}115^\circ\text{C}$; $[\alpha]_{\text{D}}^{23} -40.2$ (c 1.08, CHCl_3); IR (neat) 3200, 1652 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.81 (dd, $J = 1.5, 7.8$ Hz, 1H), 7.52 (d, $J = 7.9$ Hz, 1H), 7.20–7.40 (m, 7H), 6.61 (d, $J = 15.6$ Hz, 1H), 6.40 (dt, $J = 7.5, 15.3$ Hz, 1H), 4.53–4.61 (m, 1H), 4.49 (dd, $J = 7.9, 9.6$ Hz, 1H), 4.34 (dd, $J = 7.5, 7.5$ Hz, 1H), 4.02 (dd, $J = 5.8, 9.3$ Hz, 1H), 3.74 (d, $J = 7.6$ Hz, 2H), 3.64 (dd, $J = 3.7, 11.4$ Hz, 1H), 2.90 (t, $J = 7.5$ Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 164.3, 136.9, 136.0, 133.4, 131.3, 130.3, 129.0, 128.7, 127.7, 127.3, 126.5, 125.2, 124.9, 69.2, 68.7, 64.4, 29.4; ^{77}Se NMR (CDCl_3) 349.3; HRMS (FAB+) calcd. for $\text{C}_{19}\text{H}_{19}\text{NO}_2^{80}\text{Se}$ ($\text{M} + \text{H}^+$) 374.0659. Found 374.0666.


{2-[2-(3-Phenyl-allylselanyl)-phenyl]-4,5-dihydro-oxazol-(4S)-yl}-methanol (55)

To a stirred solution of selenide **54** (970 mg, 2.0 mmol) in THF (5 mL) at rt was sequentially added acetic acid (314 mg, 0.3 mL, 5.2 mmol) and TBAF (7.6 mL, 7.6 mmol, 1 M in THF). After 1 h, the reaction was quenched with sat. aq. NaHCO_3 (20 mL), and extracted with Et_2O (3×50 mL). The dried (MgSO_4) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 5–75% EtOAc /hexane to give **55** (700 mg, 94%) as a white solid.

(4S)-Methoxymethyl-2-[2-(3-phenyl-allylselanyl)-phenyl]-4,5-dihydro-oxazole (56)


To a stirred solution of NaH (6 mg, 0.148 mmol 60% in mineral oil) and MeI (21 mg, 9.2 μ L, 0.15 mmol) in THF (0.4 mL) at 0 °C, was added a solution of **55** (50 mg, 0.14 mmol) in THF (0.4 mL) dropwise over 5 min. After 1 h, the reaction was quenched with sat. aq. NH₄Cl (5 mL) and extracted with Et₂O (3 \times 25 mL). The dried (MgSO₄) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel eluting with 2–20% EtOAc/hexane to yield **56** (41 mg, 82%) as a white solid: mp 103–105 °C; $[\alpha]_D^{23}$ –1.6 (*c* 1.15, CHCl₃); IR (neat) 2924, 1642, 1471, 1029 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.85 (dd, *J* = 1.4, 7.8 Hz, 1H), 7.48 (d, *J* = 7.9 Hz, 1H), 7.18–7.37 (m, 7H), 6.63 (d, *J* = 15.7 Hz, 1H), 6.36 (dt, *J* = 7.8, 15.7 Hz, 1H), 4.55–4.64 (m, 1H), 4.44 (dd, *J* = 8.3, 8.3 Hz, 1H), 4.32 (dd, *J* = 7.5, 7.5 Hz, 1H), 3.71–3.75 (m, 3H), 3.47 (dd, *J* = 1.9, 7.6 Hz, 1H), 3.41 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 164.4, 137.0, 136.3, 133.2, 131.2, 130.5, 128.7, 128.4, 127.6, 126.8, 126.4, 125.1, 124.9, 75.0, 70.4, 67.0, 59.5, 28.9; HRMS (FAB+) calcd. for C₂₀H₂₂NO₂⁸⁰Se (M + H⁺) 388.0816. Found 388.0813.

(2S)-(2-Bromo-benzoylamino)-(3R)-hydroxy-butyrac methyl ester (77)



To a stirred solution of L-threonine methyl ester hydrochloride (**57**) (1.65 g, 9.7 mmol) in CH₂Cl₂ (19 mL) at 0 °C was added Et₃N (2.92 g, 4.05 mL, 29.1 mmol) and DMAP (0.297 g, 2.4 mmol). After 10 min, a solution of 2-bromobenzoyl chloride (**31**) (2.34 g, 1.4 mL, 14.9 mmol) in CH₂Cl₂ (10 mL) was added dropwise *via* syringe pump over a period of 20 min. Next, the solution was warmed to rt. After 2 h, the reaction mixture was quenched with sat. aq. NH₄Cl (25 mL) and extracted with Et₂O (3 \times 75 mL). The organic layer was sequentially washed with aq. HCl (5%, 50 mL) and sat. aq. NaHCO₃ (100 mL). The dried (MgSO₄) organic layer was concentrated *in vacuo* and purified by chromatography over silica gel, eluting with 5–100% EtOAc/hexane to give **77** (1.74 g, 58%) as a white oil: $[\alpha]_D^{23}$ +1.5 (*c* 1.91, CHCl₃); IR (neat) 3332, 1744, 1644 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.62 (dd, *J* = 1.1, 7.9 Hz, 1H), 7.55 (dd, *J* = 1.8, 7.6 Hz, 1H), 7.26–7.40 (m, 2H), 6.80 (br d, *J* = 8.1 Hz, 1H), 4.79 (dd, *J* = 2.2, 8.9 Hz, 1H), 4.44–4.49 (m, 1H), 3.81 (s, 3H), 2.28 (br s, 1H), 1.36 (d, *J* = 6.4 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 171.3, 168.1, 137.3, 133.6, 131.7, 129.8, 127.7, 119.5, 68.3, 57.8, 52.9, 20.3; HRMS (FAB+) calcd. for C₁₂H₁₅NO₄⁷⁹Br (M + H⁺) 316.0184. Found 316.0181.


(2S)-(2-Bromo-benzoylamino)-(3R)-triisopropylsilanyloxy-butyrac methyl ester (78)



To a stirred solution of amino alcohol methyl ester **77** (1.74 g, 5.52 mmol) in CH₂Cl₂ (11 mL) at 0 °C was added Et₃N (1.11 g, 1.5 mL, 11 mmol). After 10 min, TIPSOTf (4.9 g, 6 mL, 16 mmol) was added. After 1 h, the reaction was warmed to rt. After 2 h, the reaction was quenched with sat. aq. NH₄Cl (50 mL) and extracted with Et₂O (3 \times 100 mL). The dried filtrate (MgSO₄) was concentrated *in vacuo* and purified by chromatography over silica gel, eluting with 2–15% EtOAc/hex-


ane to give **78** (1.60 g, 62%) as a yellow oil: $[\alpha]_D^{23}$ –6.8 (*c* 1.14, CHCl₃); IR (neat) 1744, 1644 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.62 (dd, *J* = 7.8, 7.9 Hz, 1H), 7.55 (dd, *J* = 7.8, 7.6 Hz, 1H), 7.26–7.40 (m, 2H), 6.80 (br d, *J* = 8.1 Hz, 1H), 4.73–4.81 (m, 2H), 3.81 (s, 3H), 1.36 (d, *J* = 6.4 Hz, 3H), 1.00–1.10 (m, 21H); ¹³C NMR (75 MHz, CDCl₃) δ 170.9, 168.0, 139.0, 133.7, 132.0, 130.1, 128.4, 119.5, 69.5, 59.1, 52.5, 21.2, 18.6, 12.9; HRMS (FAB+) calcd. for C₂₁H₃₅NO₄BrSi (M + H⁺) 472.1519. Found 472.1519.

2-Bromo-N-[(1R)-hydroxymethyl-(2R)-(triisopropylsilyloxy)-propyl]-benzamide (79)



To a stirred solution of LiAlH₄ (3.51 mL, 3.51 mmol, 1.0 M in Et₂O) in THF (26 mL) at 0 °C, was added a solution of benzamide **78** (1.50 g, 3.20 mmol) in THF (17.4 mL) dropwise *via* syringe pump over 30 min. The benzamide syringe was rinsed with an additional amount of THF (2 mL). After 30 min the reaction was warmed to rt. After 2 h, the reaction was quenched with EtOAc/H₂O (100 mL, 1 : 1) and extracted with ethyl acetate (3 \times 75 mL). The dried (MgSO₄) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 2–50% EtOAc/hexane to give **79** (1.03 g, 71%) as a light pink oil: $[\alpha]_D^{23}$ –6.3 (*c* 1.61, CHCl₃); IR (neat) 2942, 1651, 1506 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.62 (dd, *J* = 1.7, 4.0 Hz, 1H), 7.60 (dd, *J* = 1.8, 4.4 Hz, 1H), 7.26–7.40 (m, 2H), 6.80 (br d, *J* = 9.0 Hz, 1H), 4.43 (dd, *J* = 4.9, 6.5 Hz, 1H), 4.08–4.10–4.20 (m, 1H), 3.77–3.88 (m, 2H), 2.66 (br s, 1H), 1.36 (d, *J* = 6.5 Hz, 3H), 1.00–1.10 (m, 21H); ¹³C NMR (75 MHz, CDCl₃) δ 168.0, 137.5, 133.7, 131.6, 130.2, 127.8, 119.2, 68.1, 64.0, 57.5, 21.7, 18.3, 12.8; HRMS (FAB+) calcd. for C₂₀H₃₅NO₃⁷⁹BrSi (M + H⁺) 444.1570. Found 444.1574.

2-(2-Bromo-phenyl)-(4R)-(triisopropyl-R-silyloxy)methyl)-4,5-dihydro-oxazole (80)



To a stirred solution of benzamide **79** (750 mg, 1.69 mmol) in CH₂Cl₂ (5 mL) at 0 °C, were added DMAP (41 mg, 0.34 mmol) and Et₃N (340 mg, 0.5 mL, 3.38 mmol). After 10 min, TsCl (600 mg, 3.04 mmol) was added and the reaction was warmed to rt. After 12 h, the reaction was quenched with sat. aq. NH₄Cl (50 mL) and extracted with Et₂O (3 \times 75 mL). The dried (MgSO₄) organic layer was concentrated *in vacuo* and purified by chromatography on silica gel, eluting with 2–20% EtOAc/hexane to give **80** (400 mg, 63%) as a light pink oil: $[\alpha]_D^{23}$ –24.0 (*c* 1.66, CHCl₃); IR (neat) 2942, 1651, 1463 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.62–7.67 (m, 2H), 7.26–7.37 (m, 2H), 4.54–4.61 (m, 2H), 4.35–4.43 (m, 2H), 1.18 (d, *J* = 5.5 Hz, 3H), 1.00–1.10 (m, 21H); ¹³C NMR (75 MHz, CDCl₃) δ 164.2, 133.9, 131.7, 131.4, 130.2, 127.2, 121.8, 72.0, 68.7, 68.4, 17.6, 17.3, 13.0; HRMS (FAB+) calcd. for C₂₀H₃₃NO₂⁷⁹BrSi (M + H⁺) 426.1464. Found 426.1477.

2-[2-(3-Phenyl-allylselanyl)-phenyl]-4(R)-(triisopropyl-R-silyloxy)methyl)-4,5-dihydro-oxazole (58)


To a stirred solution of *t*-BuLi (1.3 mL, 2.21 mmol, 1.7 M in pentane) in THF (6.7 mL) at –78 °C was added a solution of the bromide **80** (434 mg, 1.02 mmol) in THF (3.4 mL) dropwise *via* syringe pump over 20 min resulting in an orange solution.

The benzamide conical vial was further rinsed with an additional amount of THF (0.5 mL). After 1 h, Se powder (81 mg, 1.02 mmol) was added under an inverse argon funnel and the reaction was warmed to 0 °C. After 1 h or until the solution was homogeneous, cinnamyl bromide (220 mg, 0.17 mL, 1.12 mmol) was added. After 1 h, the reaction was quenched with sat. aq. NH₄Cl (20 mL) and extracted with Et₂O (3 × 75 mL). The dried (MgSO₄) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 2–20% EtOAc/hexane. The final product was recrystallized in hexane to give **58** (300 mg, 54%) as a yellow solid: mp 59–63 °C; [α]_D²³ –8.0 (c 6.50, CHCl₃). IR (neat) 2941, 1644, 1464 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.82 (dd, *J* = 1.6, 7.5 Hz, 1H), 7.49 (d, *J* = 7.9 Hz, 1H), 7.18–7.38 (m, 7H), 6.64 (d, *J* = 15.6 Hz, 1H), 6.40 (dt, *J* = 7.5, 15.0 Hz, 1H), 4.67 (dt, *J* = 4.5, 4.7 Hz, 1H), 4.55 (dd, *J* = 6.9, 8.6 Hz, 1H), 4.44 (dd, *J* = 4.5, 6.2 Hz, 1H), 4.35 (dd, *J* = 8.7, 9.9 Hz, 1H), 3.73 (d, *J* = 7.5, 2H), 1.18 (d, *J* = 6.2 Hz, 3H), 1.00–1.10 (m, 21H); ¹³C NMR (75 MHz, CDCl₃) δ 164.0, 137.1, 136.3, 133.2, 131.0, 130.4, 128.7, 128.3, 127.6, 127.0, 126.4, 125.2, 124.8, 72.3, 68.9, 67.7, 28.8, 18.3, 17.7, 12.5; HRMS (FAB+) calcd. for C₂₉H₄₂NO₂⁸⁰SeSi (M + H⁺) 544.2150. Found 544.2147.

1*R*-{2-[2-(3-Phenyl-allylselanyl)-phenyl]-4,5-dihydro-oxazol-(4*R*)-yl}-ethanol (**59**)

To a stirred solution of selenide **58** (41 mg, 0.10 mmol) in THF (0.8 mL) at rt was added acetic acid (15 mg, 13 μL, 0.2 mmol) and TBAF (1.9 mL, 1.9 mmol, 1 M in THF). After 1 h, the reaction was quenched with sat. aq. NH₄Cl (10 mL) and extracted with EtOAc (3 × 25 mL). The dried (MgSO₄) organic layer was concentrated *in vacuo* and the residue was purified by chromatography over silica gel, eluting with 2–60% EtOAc/hexane to yield **59** (52 mg, 78%) as a white solid: mp 105 °C; [α]_D²³ –11.7 (c 0.50, CHCl₃); IR (neat) 3445, 1644, 1472 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.84 (dd, *J* = 1.5, 7.7 Hz, 1H), 7.52 (d, *J* = 7.8 Hz, 1H), 7.20–7.40 (m, 7H), 6.64 (d, *J* = 15.7 Hz, 1H), 6.43 (dt, *J* = 7.4, 15.1 Hz, 1H), 4.48 (dd, *J* = 7.4, 9.3 Hz, 1H), 4.30–4.37 (m, 1H), 4.23 (dd, *J* = 7.6 Hz, 2H), 3.70 (dd, *J* = 7.0, 7.9 Hz, 2H), 2.50 (br s, 1H), 1.36 (d, *J* = 6.5 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 164.6, 136.9, 136.3, 133.3, 131.3, 130.4, 128.7, 128.7, 127.7, 126.7, 126.5, 125.1, 125.0, 73.4, 70.3, 69.6, 29.3, 20.3; HRMS (FAB+) calcd. for C₂₀H₂₂NO₂⁸⁰Se (M + H⁺) 388.0816. Found 388.0824.

4-Nitro-benzoic acid (1*S*)-{2-[2-(3-phenyl-(*E*)-allylselanyl)-phenyl]-4,5-dihydro-oxazol-(4*R*)-yl}-ethyl ester (**81**)



To a stirred solution of selenide **59** (35 mg, 0.087 mmol) in THF (0.72 mL) at –78 °C were added PPh₃ (47 mg, 0.18 mmol) and *p*-NO₂C₆H₄CO₂H (30 mg, 0.18 mmol). After 5 min, DEAD (31 mg, 28 μL, 0.18 mmol) was added dropwise to the reaction. Over 2 h, the reaction was warmed slowly from –78 °C to rt. After an additional 5 h at rt, the reaction was quenched with sat. aq. NH₄Cl (5 mL) and extracted with Et₂O (3 × 50 mL). The dried (MgSO₄) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 0.5–10% EtOAc/hexane to yield **81** (39 mg, 80%) as a white solid: mp 97–99 °C; [α]_D²³ +18.4 (c 0.50, CHCl₃); IR (neat) 1723, 1645, 1525, 1272 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 8.11–8.19 (m, 4H), 7.80–7.83 (dd, *J* = 1.1, 7.9 Hz, 1H), 7.44 (d, *J* = 8.0 Hz, 1H), 7.20–7.37 (m, 7H), 6.58 (d, *J* = 15.5 Hz, 1H), 6.31 (dt, *J* = 7.8, 15.5 Hz, 1H), 5.30–5.37 (m, 1H), 4.52–4.62 (m, 1H), 4.40–4.50 (dt, *J* = 8.8, 17.9 Hz, 2H), 3.67 (d, *J* = 7.4 Hz,

2H), 1.54 (d, *J* = 6.3 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 164.7, 164.2, 150.6, 136.9, 136.6, 135.9, 133.2, 131.4, 130.9, 130.4, 128.7, 128.4, 127.7, 126.4, 126.3, 124.9, 123.6, 74.1, 71.0, 68.8, 28.8, 17.2, 14.4; HRMS (FAB+) calcd. for C₂₇H₂₅N₂O₅⁸⁰Se (M + H⁺) 537.0929. Found 537.0942.

(1*S*)-{2-[2-(3-Phenyl-(*E*)-allylselanyl)-phenyl]-4,5-dihydro-oxazol-4*R*-yl}-ethanol (**60**)

To a stirred solution of seleno-ester **81** (37 mg, 0.070 mmol) in MeOH (0.3 mL) at rt was added K₂CO₃ (2.0 mg, 0.010 mmol). After 30 min, the reaction was quenched with sat. aq. NH₄Cl (3 mL) and extracted with EtOAc (3 × 20 mL). The dried (MgSO₄) organic layer was concentrated *in vacuo* and the residue purified by chromatography on silica gel, eluting with 2–40% EtOAc/hexane to give **60** (13 mg, 50%) as a white solid: mp 100 °C; [α]_D²³ –5.7 (c 1.20, CHCl₃); IR (neat) 3445, 1644, 1472 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.84 (dd, *J* = 1.5, 7.7 Hz, 1H), 7.52 (d, *J* = 7.8 Hz, 1H), 7.20–7.40 (m, 7H), 6.61 (d, *J* = 15.7 Hz, 1H), 6.41 (dt, *J* = 7.4, 15.1 Hz, 1H), 4.38–4.42 (m, 3H), 4.11–4.19 (m, 1H), 3.73 (d, *J* = 7.5 Hz, 2H), 2.05 (br s, 1H), 1.24 (d, *J* = 6.5 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 164.7, 136.9, 135.9, 133.3, 131.2, 130.2, 129.0, 128.7, 127.7, 126.5, 125.2, 124.9, 73.0, 68.1, 67.5, 29.4, 18.8, 14.4; HRMS (FAB+) calcd. for C₂₀H₂₁NO₂⁷⁸Se (M + H⁺) 386.0824. Found 386.0827.

2-(2-Bromo-phenyl)-4,5-dihydro-oxazole-(4*S*)-carboxylic acid methyl ester (**61**)

To a stirred solution of **50** (1.24 g, 4.10 mmol) in CH₂Cl₂ (35 mL) at –78 °C was added DAST (726 mg, 0.6 mL, 4.50 mmol) dropwise over 15 min. After 1 h, the slurry was quenched with K₂CO₃ (851 mg, 6.20 mmol) and warmed to rt. After 20 min, sat. aq. NaHCO₃ (20 mL) was added and extracted with Et₂O (3 × 75 mL). The dried (MgSO₄) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel to give **61** (1.06 g, 91%) as a light pink oil: [α]_D²³ +33.2 (c 1.31, CHCl₃); IR (neat) 2952, 1731, 1651 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.70 (dd, *J* = 1.9, 6.9 Hz, 1H), 7.62 (dd, *J* = 1.2, 7.3 Hz, 1H), 7.23–7.34 (m, 2H), 4.99 (dd, *J* = 8.0, 10.8 Hz, 1H), 4.71 (dd, *J* = 8.2, 16.9 Hz, 1H), 4.62 (dd, *J* = 8.6, 10.6 Hz, 1H), 3.78 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 171.4, 166.0, 134.0, 132.3, 131.8, 128.3, 127.3, 122.0, 69.9, 68.8, 52.9; HRMS (FAB+) calcd. for C₁₁H₁₀NO₃Br (M + H⁺) 282.9844. Found 283.9922.

1-[2-(2-Bromo-phenyl)-4,5-dihydro-oxazol-(4*S*)-yl]-2-methylpropan-1-one (**62**)


To a stirred solution **61** (2.22 g, 7.84 mmol) in THF (41 mL) at –78 °C was added *i*-PrMgCl (9.4 mL, 9.4 mmol, 1 M in Et₂O) dropwise *via* syringe pump over 60 min. After 1.5 h, the slurry was quenched with NH₄Cl and extracted with Et₂O (3 × 250 mL). The dried (MgSO₄) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel to give **62** (1.72 mg, 74%) as a light pink oil: [α]_D²³ +28.4 (c 1.19, CHCl₃); IR (neat) 2970, 1715, 1651 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.70 (dd, *J* = 1.9, 7.3 Hz, 1H), 7.66 (dd, *J* = 1.4, 7.4 Hz, 1H), 7.26–7.37 (m, 2H), 5.06 (dd, *J* = 7.4, 10.5 Hz, 1H), 4.82 (dd, *J* = 7.4, 8.5 Hz, 1H), 4.52 (dd, *J* = 8.9, 10.9 Hz, 1H), 3.25–3.35 (m, 1H), 1.27 (d, *J* = 7.2 Hz, 3H), 1.15 (d, *J* = 6.7 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 211.8, 164.6, 134.2, 132.1, 131.5, 129.2, 127.3, 122.1, 73.8, 68.5, 38.4, 18.8, 17.7; HRMS (FAB+) calcd. for C₁₃H₁₅NO₂⁷⁹Br (M + H⁺) 296.0286. Found 296.0299.

1-[2-(2-Bromo-phenyl)-4,5-dihydro-oxazol-(4*S*)-yl]-2-methylpropan-(1*R*/*S*)-ol (**63** and **64**)

To a stirred solution of **62** (250 mg, 0.9 mmol) in MeOH (3 mL) at rt was added NaBH₄ (38 mg, 1 mmol) in portions. After


30 min, the slurry was quenched with sat. aq. NH_4Cl (10 mL) and extracted with Et_2O (3×50 mL). The dried (MgSO_4) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 2–30% EtOAc/hexane to give sequentially (*S*)-(*S*) **63** (72 mg, 58%) and (*S*)-(*R*) **64** (53 mg, 42%) as white solids. **63**: $[a]_{\text{D}}^{23} + 22.5$ (c 0.98, CHCl_3); IR (neat) 3367, 2959 1715, 1654 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.63–7.68 (m, 2H), 7.26–7.37 (m, 2H), 4.50–4.64 (m, 2H), 4.20 (dt, $J = 1.0, 10.9$ Hz, 1H), 3.25 (dt, $J = 4.5, 6.7$ Hz, 1H), 2.28 (d, $J = 7.1$ Hz, 1H), 1.85–1.88 (m, 1H), 1.05 (d, $J = 6.8$ Hz, 6H); ^{13}C NMR (75 MHz, CDCl_3) δ 164.6, 133.9, 132.0, 131.3, 129.7, 127.4, 122.1, 79.1, 70.5, 69.6, 31.8, 19.7, 18.2; HRMS (FAB+) calcd. for $\text{C}_{13}\text{H}_{17}\text{NO}_2^{79}\text{Br}$ ($\text{M} + \text{H}^+$) 298.0443. Found 298.0448. **64**: $[a]_{\text{D}}^{23} + 5.9$ (c 1.02, CHCl_3); IR (neat) 3367, 2959 1715, 1654 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.62–7.67 (m, 2H), 7.26–7.37 (m, 2H), 4.39–4.56 (m, 2H), 3.72 (dd, $J = 2.8, 7.7$ Hz, 2H), 1.85 (br s, 1H), 1.71–1.77 (m, 1H), 1.07 (d, $J = 6.5$ Hz, 3H), 0.95 (d, $J = 6.8$ Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 164.8, 133.9, 131.9, 131.2, 129.9, 127.4, 122.0, 79.0, 69.8, 68.0, 30.6, 19.2, 19.0; HRMS (FAB+) calcd. for $\text{C}_{13}\text{H}_{17}\text{NO}_2^{79}\text{Br}$ ($\text{M} + \text{H}^+$) 298.0443. Found 298.0451.

2-(2-Bromo-phenyl)-(4*S*)-[(1*S*)-(tert-butyl-dimethyl-silyloxy)-2-methyl-propyl]-4,5-dihydro-oxazole (82)



To a stirred solution of **63** (70 mg, 0.24 mmol) in CH_2Cl_2 (0.5 mL) at 0 °C were sequentially added 2,6-lutidine (39 mg, 42 μL , 0.36 mmol) and TBSOTf (75 mg, 65 μL , 0.28 mmol). After 1 h, the reaction was quenched with sat. aq. NH_4Cl (5 mL) and extracted with Et_2O (3×20 mL). The dried (MgSO_4) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 1–10% EtOAc/hexane to give **82** (90 mg, 94%) as a pink oil: $[a]_{\text{D}}^{23} + 8.1$ (c 0.70, CHCl_3); IR (neat) 2956 1653, 1471 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.71 (dd, $J = 2.0, 7.5$ Hz, 1H), 7.61 (dd, $J = 1.6, 7.8$ Hz, 1H), 7.24–7.36 (m, 2H), 4.55–4.60 (m, 1H), 4.36–4.40 (m, 2H), 3.72 (dd, $J = 4.0, 5.4$ Hz, 1H), 1.85–1.95 (m, 1H), 1.03 (d, $J = 6.7$ Hz, 3H), 0.97 (d, $J = 6.8$ Hz, 3H), 0.91 (s, 9H), 0.12 (s, 3H), 0.10 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 163.6, 134.0, 131.7, 130.3, 127.2, 121.8, 77.9, 70.8, 69.6, 31.0, 26.1, 21.0, 18.5, 17.4, –3.8, –4.2; HRMS (FAB+) calcd. for $\text{C}_{19}\text{H}_{31}\text{NO}_2\text{Si}^{79}\text{Br}$ ($\text{M} + \text{H}^+$) 412.1307. Found 412.1314.

(4*S*)-[(1*S*)-(tert-Butyl-dimethyl-silyloxy)-2-methyl-propyl]-2-[2-(3-phenyl-allylselanyl)-phenyl]-4,5-dihydro-oxazole (83)




To a stirred solution of **82** (340 mg, 0.82 mmol) in THF (7.2 mL) at –78 °C was added *t*-BuLi (1.0 mL, 1.7 mmol, 1.7 M in pentane) dropwise *via* syringe pump over 20 min resulting in an orange solution. After 1 h, Se powder (65 mg, 0.82 mmol) was added to the reaction under an inverse argon funnel and warmed to 0 °C. After 2 h, cinnamyl bromide (162 mg, 0.12 mL, 0.82 mmol) was added. After 1 h, the reaction was quenched with sat. aq. NH_4Cl (10 mL) and extracted with Et_2O (3×50 mL). The dried (MgSO_4) extract was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 0–10% EtOAc/hexane to give **83** (300 mg, 71%) as a white solid: $[a]_{\text{D}}^{23} - 10.9$ (c 1.72, CHCl_3); IR (neat) 2954, 1644, 1470 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.84 (dd, $J = 1.5, 7.8$

Hz, 1H), 7.47 (d, $J = 8.1$ Hz, 1H), 7.16–7.36 (m, 7H), 6.66 (d, $J = 15.7$ Hz, 1H), 6.45 (dt, $J = 7.7, 15.7$ Hz, 1H), 4.60–4.64 (m, 1H), 4.29–4.42 (m, 2H), 3.78–3.82 (m, 1H), 3.72 (d, $J = 7.4$ Hz, 2H), 1.96–2.01 (m, 1H), 1.00 (s, 9H), 1.06 (d, $J = 6.8$ Hz, 3H), 0.98 (d, $J = 6.0$ Hz, 3H), 0.25 (s, 3H), 0.16 (s, 3H); HRMS (FAB+) calcd. for $\text{C}_{28}\text{H}_{40}\text{NO}_2\text{Si}^{80}\text{Se}$ ($\text{M} + \text{H}^+$) 530.1994. Found 530.2008.

2-Methyl-1-{2-[(3-phenyl-allylselanyl)-phenyl]-4,5-dihydro-oxazol-(4*S*)-yl}-propan-(1*S*)-ol (65)


To a stirred solution of selenide **83** (320 mg, 0.6 mmol) in CH_2Cl_2 (1.23 mL) at rt were sequentially added acetic acid (78 mg, 70 μL , 1.35 mmol) and TBAF (7.5 mL, 7.5 mmol, 1 M in THF). After 1 h the reaction was quenched with sat. aq. NH_4Cl (20 mL), and extracted with EtOAc (3×15 mL). The dried (MgSO_4) filtrate was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 2–30% EtOAc/hexane to yield **65** (134 mg, 53%) as a white solid: $[a]_{\text{D}}^{23} - 22.4$ (c 2.0, CHCl_3); IR (neat) 3209, 1651, 1449, 1253 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.81 (d, $J = 7.8$ Hz, 1H), 7.51 (d, $J = 8.0$ Hz, 1H), 7.20–7.39 (m, 7H), 6.59 (d, $J = 15.7$ Hz, 1H), 6.37 (dt, $J = 7.3, 15.4$ Hz, 1H), 4.54–4.58 (m, 1H), 4.47 (dd, $J = 7.8, 7.8$ Hz, 1H), 4.23 (dd, $J = 7.7, 7.7$ Hz, 1H), 3.72 (d, $J = 7.5$ Hz, 2H), 3.23 (dd, $J = 7.1, 11.8$ Hz, 1H), 2.29 (d, $J = 7.7$ Hz, 1H), 1.90–1.97 (m, 1H), 1.07 (d, $J = 6.7$ Hz, 3H), 1.06 (d, $J = 6.7$ Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 164.8, 137.2, 136.4, 133.5, 131.5, 130.5, 129.0, 128.9, 127.9, 127.2, 126.7, 125.3, 79.2, 70.4, 69.9, 32.4, 29.6, 20.0, 18.6; HRMS (FAB+) calcd. for $\text{C}_{22}\text{H}_{26}\text{NO}_2^{80}\text{Se}$ ($\text{M} + \text{H}^+$) 416.1129. Found 416.1134.

2-(2-Bromo-phenyl)-(4*S*)-[(1*R*)-(tert-butyl-dimethyl-silyloxy)-2-methyl-propyl]-4,5-dihydro-oxazole (84)



To a stirred solution of **64** (57 mg, 0.19 mmol) in CH_2Cl_2 (0.4 mL) at 0 °C were sequentially added 2,6-lutidine (32 mg, 27 μL , 0.29 mmol) and TBSOTf (61 mg, 52 μL , 0.23 mmol). After 1 h, the reaction was quenched with sat. aq. NH_4Cl (5 mL) and extracted with Et_2O (3×20 mL). The dried (MgSO_4) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 1–10% EtOAc/hexane to give **84** (48 mg, 62%) as a light pink oil: $[a]_{\text{D}}^{23} + 1.7$ (c 0.78, CHCl_3); IR (neat) 2956, 1653, 1471 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.76 (dd, $J = 2.0, 7.5$ Hz, 1H), 7.64 (dd, $J = 1.6, 7.8$ Hz, 1H), 7.24–7.36 (m, 2H), 4.53 (dd, $J = 5.7, 7.0$ Hz, 1H), 4.33–4.36 (m, 2H), 3.99 (dd, $J = 2.0, 4.2$ Hz, 1H), 1.81–1.87 (m, 1H), 0.96 (d, $J = 7.0$ Hz, 3H), 0.92 (d, $J = 4.3$ Hz, 3H), 0.90 (s, 9H), 0.07 (s, 3H), –0.02 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 163.6, 134.0, 131.7, 130.3, 127.2, 121.8, 77.9, 70.8, 69.6, 31.0, 26.1, 21.0, 18.5, 17.4, –3.8, –4.2; HRMS (FAB+) calcd. for $\text{C}_{19}\text{H}_{31}\text{NO}_2\text{Si}^{79}\text{Br}$ ($\text{M} + \text{H}^+$) 412.1307. Found 412.1318.

(4*S*)-[(1*R*)-(tert-Butyl-dimethyl-silyloxy)-2-methyl-propyl]-2-[2-(3-phenyl-(*E*)-allylselanyl)-phenyl]-4,5-dihydro-oxazole (85)




To a stirred solution of bromide **84** (176 mg, 0.43 mmol) in THF (3.8 mL) at –78 °C was added *t*-BuLi (0.5 mL,

0.85 mmol, 1.7 M in pentane) dropwise *via* syringe pump over 20 min resulting in an orange solution. After 1 h, Se powder (36 mg, 0.43 mmol) was added to the reaction under an inverse argon funnel and warmed to 0 °C. After 2 h, cinnamyl bromide (63 mg, 63 µL, 0.43 mmol) was added. After 1 h, the reaction was quenched with sat. aq. NH₄Cl (10 mL) and extracted with Et₂O (3 × 50 mL). The dried (MgSO₄) extract was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 0–10% EtOAc/hexane to give **85** (169 mg, 74%) as a white solid: mp 122 °C; [α]_D²³ –44.2 (*c* 1.23, CHCl₃); IR (neat) 2954, 1644, 1470 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.83 (dd, *J* = 1.5, 7.8 Hz, 1H), 7.46 (d, *J* = 8.1 Hz, 1H), 7.16–7.36 (m, 7H), 6.62 (d, *J* = 15.7 Hz, 1H), 6.39 (dt, *J* = 7.7, 15.7 Hz, 1H), 4.43–4.50 (m, 2H), 4.27–4.33 (m, 1H), 3.92 (dd, *J* = 2.2, 4.2 Hz, 1H), 3.71 (d, *J* = 7.4 Hz, 2H), 1.82–1.87 (m, 1H), 0.96 (d, *J* = 7.0 Hz, 3H), 0.92 (d, *J* = 6.1 Hz, 3H), 0.88 (s, 9 H), 0.05 (s, 3H), –0.11 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 163.2, 137.1, 136.4, 133.1, 130.8, 130.4, 128.8, 128.7, 128.1, 127.6, 126.8, 126.5, 125.3, 124.7, 78.3, 70.0, 67.7, 33.5, 26.1, 19.0, 18.5, 18.4, –3.9, –4.0; HRMS (FAB+) calcd. for C₂₈H₁₀NO₂Si⁸⁰Se (M + H⁺) 530.1994. Found 530.1994.

2-Methyl-1-{2-[2-(3-phenyl(*E*)-allylselanyl)-phenyl]-4,5-dihydro-oxazol-(4*S*)-yl]-propan-(1*R*)-ol (66)

To a stirred solution of selenide **85** (195 mg, 0.38 mmol) in CH₂Cl₂ (1 mL) at rt was sequentially added acetic acid (44 mg, 42 µL, 0.74 mmol) and TBAF (2.1 mL, 2.1 mmol, 1 M in THF). After 1 h, the reaction was quenched with sat. aq. NH₄Cl (20 mL) and extracted with EtOAc (3 × 20 mL). The dried (MgSO₄) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 2–30% EtOAc/hexane to give **66** (75 mg, 60%) as a white solid: mp 125 °C; [α]_D²³ –22.4 (*c* 2.0, CHCl₃); IR (neat) 3209, 1651, 1449, 1253 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.70 (dd, *J* = 1.2, 7.60 Hz, 1H), 7.50 (d, *J* = 8.0 Hz, 1H), 7.20–7.39 (m, 7H), 6.58 (d, *J* = 15.7 Hz, 1H), 6.40 (dt, *J* = 7.3, 15.4 Hz, 1H), 4.56–4.64 (m, 1H), 4.37–4.41 (m, 2H), 3.71–3.76 (m, 3H), 2.12 (br s, 1H), 1.66–1.79 (m, 1H), 1.09 (d, *J* = 6.6 Hz, 3H), 0.95 (d, *J* = 6.8 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 164.6, 136.9, 135.9, 133.3, 131.2, 130.1, 129.0, 128.7, 127.7, 127.4, 126.5, 125.2, 125.0, 77.7, 70.0, 67.5, 30.6, 29.4, 19.3, 19.2; ⁷⁷Se NMR (CDCl₃) 349.0; HRMS (FAB+) calcd. for C₂₂H₂₆NO₂⁷⁸Se (M + H⁺) 414.1137. Found 414.1133.

(4*S*)-[(1*R*)-(tert-Butyl-dimethyl-silyloxy)-2-methyl-propyl]-2-[2-(3-phenyl(*Z*)-allylselanyl)-phenyl]-4,5-dihydro-oxazole (86)



To a stirred solution of bromide **85** (150 mg, 0.37 mmol) in THF (1.2 mL) at –78 °C was added *t*-BuLi (0.45 mL, 0.77 mmol, 1.7 M in pentane) dropwise *via* syringe pump over 20 min resulting in an orange solution. After 1 h, Se powder (29 mg, 0.37 mmol) was added to the reaction under an inverse argon funnel and warmed to 0 °C. After 2 h, *Z*-cinnamyl chloride³⁴ (70 mg, 0.43 mmol) was added. After 1 h, the reaction was quenched with sat. aq. NH₄Cl (10 mL) and extracted with Et₂O (3 × 50 mL). The dried (MgSO₄) extract was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 2–20% EtOAc/hexane to give impure **86** (76 mg) which was used in the next transformation without any additional purification.

2-Methyl-1-{2-[2-(3-phenyl(*Z*)-allylselanyl)-phenyl]-4,5-dihydro-oxazol-(4*S*)-yl]-propan-(1*R*)-ol (67)

To a stirred solution of selenide impure **86** (76 mg, 0.14 mmol) in CH₂Cl₂ (0.3 mL) at rt was sequentially added acetic acid (17 µL, 0.28 mmol) and TBAF (2.8 mL, 2.8 mmol, 1 M in THF). After 24 h, the reaction was quenched with sat. aq. NH₄Cl (20 mL) and extracted with Et₂O (3 × 20 mL). The dried (MgSO₄) organic layer was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 2–30% EtOAc/hexane to give **67** (15 mg, 10% over 2 steps) as a white solid: The white solid was recrystallized twice in hexane to give a white solid: mp 58 °C; [α]_D²³ +11.3 (*c* 0.4, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 7.78–7.82 (m, 1H), 7.16–7.38 (m, 8H), 6.56 (d, *J* = 11.3 Hz, 1H), 5.90 (dt, *J* = 8.5, 11.5 Hz, 1H), 4.44–4.66 (m, 2H), 4.23 (dd, *J* = 9.3, 17.1 Hz, 1H), 3.73–3.91 (m, 2H), 3.20 (dt, *J* = 4.9, 6.9 Hz, 1H), 2.30 (d, *J* = 7.4 Hz, 1H), 1.89–2.0 (m, 1H), 1.09 (d, *J* = 2.6 Hz, 3H), 1.07 (d, *J* = 2.6 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) 164.6, 136.8, 136.4, 132.2, 131.3, 130.3, 129.0, 128.7, 128.6, 127.4, 127.0, 126.6, 124.9, 79.0, 70.2, 69.7, 32.2, 25.1, 19.8, 18.4; HRMS (FAB+) calcd. for C₂₂H₂₆NO₂⁷⁸Se (M + H⁺) 414.1137. Found 414.1127.

General procedure for vanadium-catalyzed ASOS reaction with bidentate oxazoles [1-phenyl-prop-2-en-1-ol (10e)]

To a stirred solution of the selenide (1 mmol) in CH₂Cl₂ (4 mL) at rt was added VO(acac)₂ (10 mol%) and powdered 4 Å mol. sieves (500 mg per mmol selenide). After 20 min, the reaction was cooled to –50 °C and TBHP (2 mmol, 5.5 M in decane) was added. After 12–20 h, the reaction was quenched with PBU₃ (1.3 mmol). After 10 min, the slurry was diluted with sat. aq. NH₄Cl (50 mL) and extracted with Et₂O (3 × 200 mL). The dried (MgSO₄) filtrate was concentrated *in vacuo* and the residue was purified by chromatography on silica gel, eluting with 2–20% EtOAc/hexane to yield **10e** as a pale yellow oil. The diastereomeric excess was determined *via* conversion to the Mosher ester using ¹H and/or ¹⁹F NMR in C₆D₆.

Acknowledgements

Financial support was provided by the National Institutes of Health (NIH) (GM63723), University of Mississippi and Oregon State University. This publication was also made possible in part by a grant from the NIH – National Institute of Environmental Health Sciences (P30 ES00210). The authors would like to thank Professor Max Dienzer (Mass Spectrometry Facility, Environmental Health Sciences Center, Oregon State University) and Dr Jeff Morr  (Mass Spectrometry Facility, Environmental Health Sciences Center, Oregon State University) for mass spectra data, Roger Kohnert (Oregon State University) and Professor David E. Graves (University of Alabama-Birmingham) for NMR assistance and Dr Roger Hanselmann (Rib-X Pharmaceuticals) for his helpful discussions.

References

- (a) E. J. Corey and C. J. Helal, *Angew. Chem., Int. Ed.*, 1998, **37**, 1986; (b) T. Ohkuma, M. Koizumi, H. Doucet, T. Pham, M. Kozawa, K. Murata, E. Katayama, T. Yokozawa, T. Ikariya and R. Noyori, *J. Am. Chem. Soc.*, 1998, **120**, 13529; (c) Y. Gao, R. M. Hanson, J. M. Klunder, S. Y. Ko, H. Masamune and K. B. Sharpless, *J. Am. Chem. Soc.*, 1987, **109**, 5765; (d) P. Knochel in *Handbook of Reagents for Organic Synthesis: Reagents, Auxiliaries and Catalysts for C–C Bonds*, ed. R. M. Coates and S. E. Denmark, John Wiley & Sons, New York, 1999, pp. 270–75.
- A. H. Hoveyda, D. A. Evans and G. C. Fu, *Chem. Rev.*, 1993, **93**, 1307.
- K. C. Nicolaou and E. J. Sorenson, *Classics in Total Synthesis*, VCH press, New York, 1996.
- (a) T. Wirth, *Angew. Chem., Int. Ed.*, 2000, **39**, 3740; (b) Y. Nishibayashi and S. Uemura in *Organoselenium Chemistry-A*

- Practical Approach*, ed. T. G. Back, Oxford University Press, Oxford, 1999, pp. 207–221; (c) N. Komatsu and S. Uemura in *Advances in Detailed Reaction Mechanisms: Volume 4*, ed. J. M. Coxon, JAI Press, 1995, pp. 73–92; (d) H. J. Reich in *Organoselenium Chemistry*, ed. D. Liotta, John Wiley & Sons, New York, 1987, pp. 365–93; (e) S. Uemura, *Phosph. Sulf. and Sil.*, 2001, **171–172**, 13.
- 5 It should be noted that a sulfur-based variant for the SOS reaction (the Mislow–Braverman–Evans rearrangement) is well-known and has been extensively reviewed. (a) D. K. Jones-Hertzog and W. L. Jorgensen, *J. Org. Chem.*, 1995, **60**, 6682; (b) D. A. Evans and G. C. Andrews, *Acc. Chem. Res.*, 1974, **7**, 147.
- 6 The Mislow–Braverman–Evans rearrangement has been employed in total synthesis. (a) A. K. Mapp and C. H. Heathcock, *J. Org. Chem.*, 1999, **64**, 23; (b) L. A. Paquette, P. G. Meister, D. Friedrich and D. R. Sauer, *J. Am. Chem. Soc.*, 1993, **115**, 49.
- 7 R. G. Carter and T. C. Bourland, *Chem. Commun.*, 2000, 2031.
- 8 Selected examples of enzymatic and nitrogen oxide-based processes for oxidation of selenides have been reported. (a) Nitrogen oxide catalysis: E. Bosch and J. K. Kochi, *J. Chem. Soc., Perkin Trans. 1*, 1996, 2731; (b) Enzymatic catalysis: G.-P. Chen and D. M. Ziegler, *Arch. Biochem. Biophys.*, 1994, **312**, 566; (c) T. P. M. Akerboom, H. Sies and D. M. Ziegler, *Arch. Biochem. Biophys.*, 1995, **316**, 220.
- 9 H. J. Reich, K. E. Yelm and S. Wollowitz, *J. Am. Chem. Soc.*, 1983, **105**, 2503.
- 10 F. A. Davis and R. T. Reddy, *J. Org. Chem.*, 1992, **57**, 2599.
- 11 N. Kurose, T. Takahashi and T. Koizumi, *Tetrahedron*, 1997, **53**, 12115.
- 12 Y. Nishibayashi, J. D. Singh, S. Fukuzawa and S. Uemura, *J. Org. Chem.*, 1995, **60**, 4114.
- 13 K. Fujita, M. Kanakubo, H. Ushijima, A. Oishi, Y. Ikeda and Y. Taguchi, *Synlett*, 1998, 987.
- 14 H. J. Reich and K. E. Yelm, *J. Org. Chem.*, 1991, **56**, 5672.
- 15 N. Komatsu, Y. Nishibayashi and S. Uemura, *Tetrahedron Lett.*, 1993, **34**, 2339.
- 16 (a) Y. Gao, R. M. Hanson, J. M. Klunder, S. Y. Ko, H. Masamune and K. B. Sharpless, *J. Am. Chem. Soc.*, 1987, **109**, 5765; (b) H. B. Kagan and P. Pitchen, *Tetrahedron Lett.*, 1984, **25**, 1049.
- 17 M. Tiecco, M. Tingoli, L. Testaferri and D. Bartoli, *Tetrahedron Lett.*, 1987, **28**, 3849.
- 18 T. Shimizu, M. Kobayashi and N. Kamigata, *Sulfur Lett.*, 1988, **8**, 61.
- 19 For a general review of vanadium chemistry, see: T. Hirao, *Chem. Rev.*, 1997, **97**, 2707.
- 20 (a) D. A. Cogan, G. Liu, K. Kim, B. Backes and J. Ellman, *J. Am. Chem. Soc.*, 1998, **120**, 8011; (b) C. Bolm and F. Bienwald, *Angew. Chem., Int. Ed. Engl.*, 1995, **34**, 2640; (c) K. Nakijima, M. Kojima and J. Fujita, *Chem. Lett.*, 1986, 1483.
- 21 D. L. Comins and A. Dehgagani, *J. Org. Chem.*, 1995, **60**, 794.
- 22 D. A. Evans, M. D. Ennis and D. J. Mathre, *J. Am. Chem. Soc.*, 1982, **104**, 1737.
- 23 This steric interaction between the aryl group on the selenide and the Z-substituent on the alkene has been put forth by other laboratories to explain the increased levels of selectivity observed in *cis*-alkene systems.
- 24 J. F. Bower, C. J. Martin, D. J. Rawson, M. Z. A. Slawin and J. M. J. Williams, *J. Chem. Soc., Perkin Trans. 1*, 1996, 331.
- 25 Q. Zhou and A. Pfaltz, *Tetrahedron*, 1994, **50**, 4467.
- 26 (a) A. M'Boungou-M'Passi, F. Henin and J. P. Muzart, *Bull. Soc. Chim. Fr.*, 1993, **130**, 214; (b) R. E. Gawley and P. Zhang, *J. Org. Chem.*, 1996, **61**, 8103; (c) R. A. Chittenden and G. H. Cooper, *J. Chem. Soc. C*, 1970, 49.
- 27 M. C. Pirrung and N. L. Tumey, *J. Comb. Chem.*, 2000, **2**, 675.
- 28 (a) A. Panda, G. Mugesh, H. B. Singh and R. J. Butcher, *Organometallics*, 1999, **18**, 1986; (b) G. Mugesh, A. Panda, H. B. Singh and R. J. Butcher, *Chem. Eur. J.*, 1999, **5**, 1411; (c) G. Mugesh, H. B. Singh and R. J. Butcher, *Tetrahedron: Asymmetry*, 1999, **10**, 237.
- 29 (a) G. A. Keck and S. Castellino, *Tetrahedron Lett.*, 1987, **28**, 281; (b) S. V. Frye and E. Eliel, *Tetrahedron Lett.*, 1986, **27**, 3223. It should be noted that there have been selected examples reported to the contrary; (c) P. G. Willard and M. J. Hintze, *J. Am. Chem. Soc.*, 1987, **109**, 5539; (d) D. A. Evans, B. D. Allison and M. G. Yang, *Tetrahedron Lett.*, 1999, **40**, 4457; (e) D. A. Evans, D. P. Halstead and B. D. Allison, *Tetrahedron Lett.*, 1999, **40**, 4461.
- 30 M.-J. Chen, K. Narkunan and R.-S. Liu, *J. Org. Chem.*, 1999, **64**, 8311.
- 31 A. J. Phillips, Y. Uto, P. Wipf, M. J. Reno and D. R. Williams, *Org. Lett.*, 2000, **2**, 1165.
- 32 L. M. Mascavage, Q. Lu, J. Vey, D. R. Dalton and P. J. Carroll, *J. Org. Chem.*, 2001, **66**, 3621 and references cited within.
- 33 Selected examples have been reported that support this hypothesis. (a) T. Onishi, Y. Otake, N. Hirose, T. Nakano, T. Torii, M. Nakazawa and K. Izawa, *Tetrahedron Lett.*, 2001, **42**, 6337; (b) P. Delair, C. Einhorn, J. Einhorn and J. L. Luche, *J. Org. Chem.*, 1999, **59**, 4680.
- 34 The substrate **67** was made in an analogous fashion as described previously. The Z-alkene was incorporated by alkylation of the selenolate by Z-cinnamyl chloride. This chloride was prepared using the protocol outlined by Davis and co-workers.¹⁰ It should be noted that the corresponding Z-cinnamyl iodide proved problematic, as considerable isomerization was observed during its formation from the corresponding Z-allylic alcohol.
- 35 D. D. Perrin and W. L. F. Armarego, *Purification of Laboratory Chemicals: Third Edition*, Pergamon Press, New York, 1993.